

Agenda

10 September 2026

8:00 am - 10:00 am
Peripheral Artery Disease

Scientific Session - [Vascular Surgery](#), [Vascular Nursing](#)

8:00 am

[Welcome to ANZSVS QTN 2026](#)

8:10 am

[PAD: adverse impacts, disparities in outcomes and the path ahead](#)
[Jonathan Colledge](#)

8:18 am

[Directional Atherectomy Followed by DCB: A Strategy for Complex Femoropopliteal Disease](#)
[Nick Mouawad](#)

8:26 am

[An update on E-Femoral - First In Human Trial](#)
[Manar Khashram](#)

8:32 am

[Long-Term Outcomes of Directional Versus Rotational Atherectomy for Femoropopliteal Artery Disease: A Multi-Centre Study](#)
[James Colbourne](#)

Background: Directional (HawkOne/TurboHawk) and rotational (Jetstream) atherectomy are increasingly used in the management of femoral-popliteal steno-occlusive disease. There is little real-world data comparing the long-term outcomes of the two different devices. Methods: A retrospective multi-institutional cohort study was conducted evaluating both efficacy (technical success, 12-month primary patency, target-lesion revascularisation rates) and safety outcomes (complication rate, major limb amputation, mortality). Outcomes were compared by device in addition to a subgroup analysis of in-stent lesions (ISR). They were compared using Fisher exact tests, multivariable logistic regression and propensity-score matching. Results: Across 163 limbs, median age was 71 years, 36 (22%) were female, 40% had chronic limb-threatening ischaemia, 44% were diabetic, and the modal lesion was TASC II. HawkOne/TurboHawk (n=47) trended toward fewer periprocedural complications than Jetstream (n=116) (17% vs 35%; adjusted OR 0.39, 95% CI 0.16 to 0.95, p=0.04) with no device difference seen for patency, TLR, mortality or amputation. ISR lesions (n=35) had a significantly lower 12-month patency loss than native lesions (68.8% vs 34.7%; p=0.001), independent of device (adjusted OR 3.93, 95% CI 1.68 to 9.19, p=0.002). Conclusions: Atherectomy device did not independently affect any of the evaluated efficacy outcomes. The trend toward fewer complications with directional atherectomy warrants prospective evaluation. ISR lesions conferred a four-fold lower 12-month patency rate when compared to native lesions.

8:38 am

[Pulsatile Intravascular Lithotripsy for Heavily Calcified Femoropopliteal Arterial Disease: First-in-Human Results from the POWER PAD I Feasibility Study](#)
[Davina Daudu](#)

Background: Severe femoropopliteal calcification increases endovascular complexity and is associated with impaired luminal gain, vessel injury, restenosis and bailout stenting. Pulsatile intravascular lithotripsy (PIVL) delivers hydraulic pressure waves through a non-compliant balloon. POWER PAD I evaluated first-in-human feasibility and safety of PIVL in calcified femoropopliteal disease. Methods: POWER PAD I was a prospective, single-arm, two-centre study. Adults with Rutherford 2-4 symptomatic peripheral arterial disease and calcified superficial femoral or popliteal lesions underwent PIVL, with adjunctive therapy as indicated. Angiographic and duplex outcomes were core-lab assessed; adverse events independently adjudicated. Results: Nine patients underwent treatment of 20 lesions. Mean age was 76.2 ± 12.6 years, five were male, 19 lesions were severely calcified and five were chronic total occlusions. Device and procedural success were achieved in 8/9 patients, and technical success in 9/9. All 15 balloons were delivered, inflated, deflated and

retrieved. One balloon ruptured after therapy delivery, causing automatic system shut-off without clinical sequelae. Mean diameter stenosis improved from $76.5 \pm 18.0\%$ to $28.1 \pm 6.9\%$ after PIVL and $20.6 \pm 5.8\%$ after adjunctive therapy. Mean minimal luminal diameter increased from 1.3 ± 1.0 mm to 3.8 ± 0.5 mm after PIVL and 4.3 ± 0.6 mm at final angiography. There was no perforation, distal embolisation, thrombus, abrupt closure, no-reflow, bailout stenting, or grade D or higher dissection. Freedom from clinically driven target-lesion revascularisation was 100% at 30 days and 6 months, with one event by 12 months. Conclusions: In this first-in-human study, PIVL was feasible for heavily calcified femoropopliteal lesions, achieving substantial acute luminal gain without severe vessel-wall complications or bailout stenting. Larger controlled studies with longer follow-up and intravascular imaging are warranted.

8:44 am

[Discussion](#)

8:49 am

[The Foot-PAD Trial: A Double-Blind, Randomised Placebo-Controlled Trial of Footplate Neuromuscular Electrical Stimulation on Walking Capacity in Patients with PAD](#)

[Christopher Askew](#)

Purpose: Patients with peripheral artery disease (PAD) experience leg muscle pain that limits walking and the ability to adhere to exercise therapy. Neuromuscular electrical stimulation (NMES) induces exercise-like muscle contractions and can be performed without pain. We hypothesised that a 12-week program of NMES would improve walking capacity compared with placebo-control in patients with PAD. Methodology: This was a single-centre, double-blind, randomised placebo-controlled trial. 180 patients with PAD (n=90 per group; mean age: 72 ± 9 y; ABI: 0.69 ± 0.20) were randomised to a 12-week program of NMES or sham placebo-control (CON). This was followed by a 6-week off-intervention follow-up. Outcomes were assessed at baseline (week 0), midway (week 6) and at the end of the intervention period (week 12), and again at the end of the follow-up phase (week 18). Participants used a footplate-NMES device (Revitive Medic Coach) for 2x30 min periods each day to deliver stimulation sufficient to induce contraction of the leg muscles. Control participants used a sham device that does not induce muscle contraction. Primary outcome was maximum distance during the six-minute walk test (6MWT). Secondary outcomes included pain-free distance during the 6MWT, and maximum and pain-free walking time during a graded treadmill test. Results: There was no difference in 6MWT distance between groups at week 12 (marginal mean difference (MMD): 3.68 m; 95% CI: -4.21 to 11.56; $P = 0.361$). At week 18, six weeks after the intervention ceased, 6MWT distance was greater in the NMES group compared with CON (MMD: 10.77 m; 95% CI: 2.82 to 18.72; $P = 0.008$). Pain-free 6MWT distance increased and was greater in the NMES group compared with CON at week 12 (MMD: 23.08 m; 95% CI: 6.55 to 39.61; $P = 0.024$). Conclusion: NMES may represent a valuable adjunct therapy to improve symptoms in patients with PAD.

8:57 am

[The contemporary patterns of endovascular surgery for peripheral arterial disease in Australia and Aotearoa New Zealand](#)

[Mike Wu](#)

Purpose The endovascular treatment of peripheral arterial disease (PAD) has grown compared to open surgical procedures, to a greater degree in some states than others. This could be due to state-related differences in population health, health system structures and resources, and privately-insured status. We examined PAD procedures in terms of state and insurance status of patients to better understand the contemporary patterns of practice in Australia and Aotearoa New Zealand. Methodology Using AVA data on all the consecutive procedures performed in 2021 to 2023 for PAD in Australia and Aotearoa New Zealand, the 5 most common indications for PAD interventions were examined by state and by financial class. The data was analysed in R using summary statistics, multinomial logistic regression and generalised linear models. Results There were 30200 endovascular procedures for PAD between 2021 and 2023. 29370 procedures occurred in Australia and 830 in Aotearoa New Zealand. Using Australian Capital Territory (ACT) as the reference state, most other states had a higher rate of intervention ($p < 0.01$), Victoria had the same rate, and Northern Territory had a lower rate ($p < 0.01$). There is a significant positive correlation between private-to-public ratio and intervention rate across the states for all indications combined. After controlling for state, public patients compared to private have 65% lower odds for claudication, 53% lower odds for rest pain and 24% lower odds for ulcer as the intervention indication. Conclusion In Australia, the states with higher rates of interventions also had higher ratios of private to public patients.

9:05 am

[Angiosome-directed revascularization in chronic limb-threatening ischemia: insights from a nine-year multicentre retrospective cohort study](#)

[Man Yuen Arthur Fung](#)

9:11 am

[Chemical Lumbar Sympathectomy in Non-Revascularised Chronic Limb Threatening Ischaemia: A Retrospective Single-Centre Cohort Study](#)
[Tin Yau Ngan](#)

Background Management options for patients with chronic limb-threatening ischaemia (CLTI) that do not undergo revascularisation remain limited, particularly when major intervention is not feasible or is being deferred. Chemical lumbar sympathectomy (CLS) is used in some centres as an adjunct for ischaemic pain, but contemporary outcome data are sparse. This study evaluated short-term symptomatic response and limb outcomes following CLS in a tertiary referral practice. Methods A retrospective single-centre cohort study was performed of patients undergoing CLS between 2015 and 2025. Patients treated for peripheral arterial disease/CLTI were identified from institutional records. Baseline demographic, clinical and procedural data were extracted from the electronic medical record. Outcomes included early subjective pain response, procedure-related complications, minor amputation, major amputation and in-hospital death. Exploratory analyses assessed associations between baseline characteristics and pain response. Results Sixty limbs underwent CLS during the study period; 47 procedures were performed for peripheral arterial disease. Mean age was 73 years and 50% of patients were male. Early pain reduction was documented in 25/46 evaluable cases (54.3%). Reintervention occurred in 11 patients (18.3%), minor amputation in 7 (11.7%), major amputation in 8 (13.3%), and death during the index admission in 4 (6.7%). Procedure-related major complications were rare, with one patient (1.7%) sustaining acute spinal syndrome with associated bowel/bladder dysfunction. Conclusion In a contemporary single-centre experience, CLS was used as an adjunct in a high-risk cohort with limb ischaemia that did not undergo revascularisation. CLS was associated with early pain improvement in approximately half of evaluable patients, with a low rate of serious procedural complications.

9:17 am

[Paywalled Protection: The Socioeconomic Divide in AI-Generated Health Literacy for Peripheral Arterial Disease.](#)
[Mina Mikhael](#)

Purpose: Patients increasingly utilise artificial intelligence (AI) for medical advice. While socioeconomic inequality in vascular healthcare is well-documented, the disparity in AI health literacy remains a critical gap in literature. This novel study compares the clinical accuracy, readability, and safety of free versus premium large language models (LLMs) in peripheral arterial disease (PAD) to evaluate this emerging digital divide. Methodology: Fifteen standardised PAD queries were inputted into three free LLMs (ChatGPT, Claude 4.6 Sonnet, Gemini 3.5 Flash) and their premium counterparts (GPT-5.5, Claude 4.8 Opus, Gemini 3.1 Pro). Clinical quality was graded using the validated 16-item DISCERN instrument. Readability was assessed via the Flesch-Kincaid Grade Level (FKGL). The frequency of universal safety-netting (explicitly advising medical review) was tracked across all 15 prompts. Results: Premium LLMs demonstrated superior clinical reliability (mean DISCERN 55.0 vs 50.1) and nuanced differential diagnosis. Crucially, safety alerts advising urgent medical review were markedly higher in premium models (up to 93% via hard-coded disclaimers) compared to free versions (47%–60%). Readability was universally poor (FKGL 8.5–12.6, requiring up to a university reading level), vastly exceeding the Grade 6 health literacy target. Notably, one free model exhibited algorithmic hallucination by leaking its internal system prompt, demonstrating the unpredictability of unregulated AI. Conclusion: Premium AI provides significantly safer PAD education than free versions. For lower socioeconomic patients, reliance on unregulated free AI risks compounding existing vascular inequities and delaying presentation for chronic limb-threatening ischaemia (CLTI). Vascular surgeons must actively mitigate this digital wealth gap by prescribing verified resources. Future research should focus on developing equitable, open-access medical AI featuring mandatory triage safety-netting and low-literacy adaptations.

9:23 am

[Discussion](#)

9:31 am

[Comparing BEST-CLI participants with patients treated at a tertiary centre serving a regional-remote population](#)
[David Sun](#)

9:37 am

[Outcomes of Revascularisation for Treating Lifestyle-Limiting Intermittent Claudication in Aboriginal and Torres Strait Islander People and Non-Indigenous Patients from North Queensland: A Retrospective Cohort Study](#)

[Shannon Wong](#)

Background: This retrospective analysis of an ongoing prospective cohort study aimed to assess the outcome of revascularisation for treating lifestyle-limiting intermittent claudication caused by peripheral artery disease (PAD) in Aboriginal and Torres Strait Islander Peoples and non-Indigenous North Queenslanders. Methods: Consenting patients with PAD who underwent endovascular or open revascularisation procedures for treating lifestyle-limiting intermittent claudication were included. The primary outcome measure was major adverse limb events (MALEs), defined as major amputation or the requirement for repeat open or endovascular revascularisation. Results: Of the 378 included patients, 18 (4.8%) identified as Aboriginal and/or Torres Strait Islander Peoples. During a mean follow-up (standard deviation) of 6.0 (3.9) years, the incidence of MALE was similar in the Aboriginal and Torres Strait Islander People and non-Indigenous Australians (absolute percentage: 50.0% vs. 40.6%, log rank $p = 0.59$). In both unadjusted and adjusted analyses, Aboriginal and Torres Strait Islander Peoples and non-Indigenous Australians had similar risks of MALE (unadjusted hazard ratio, HR, 1.20, 95% confidence interval, CI, 0.61, 2.36; adjusted HR 1.02, 95%CI 0.50, 2.06). Conclusions: This study suggests that Aboriginal and Torres Strait Islander People are under-represented in the population of patients undergoing revascularisation to treat intermittent claudication. Due to small numbers it cannot be reliably concluded that Aboriginal and Torres Strait Islander People and non-Indigenous Australians have similar rates of MALE.

9:43 am

[Beyond the Statin: Distinct Patterns of Persistent LDL-C Non-Control in Peripheral Artery Disease](#) [Oliver Zhang](#)

Purpose: PAD is associated with high cardiovascular risk, and recent guidelines recommend substantially lower LDL-C, requiring treatment escalation beyond routine statin prescribing. Vascular practice commonly relies on indicators such as statin use, which may not reflect adequate LDL-C control. Lipid control is influenced by multiple interacting factors, including treatment intensity, patient factors, and system-level constraints. As a result, patients with similar lipid levels may differ substantially in their required level of intervention. This study aimed to identify lipid management patterns in the TEAM-PAD RCT, determining associations with recognisable patient characteristics. Methodology: The TEAM-PAD RCT allocated patients with PAD to MDT or routine vascular care. We analysed lipid profiles at baseline and 9-months and performed hierarchical cluster analysis using LDL-C target achievement, number of lipid-lowering therapy (LLT) agents, and high-intensity statin use at 9-months in 123 patients with complete data. Clusters were described using clinical and demographic characteristics, with before and after comparison. Results: At 9-months, 62 patients (50.4%) had not achieved LDL-C targets, occurring in two distinct clusters. The first had limited treatment ($n=34$). None were on high-intensity statins, with 41% on no LLT. The second had residual poor-control despite high-intensity statins ($n=28$) but 79% were on statin monotherapy. Overall, 45 of 62 patients not at target were on a statin (73%). Persistent non-control was not identifiable by PAD severity ($p=0.868$), prior vascular procedures ($p=0.125$), or MDT allocation ($p=0.718$). Of 63 patients not at target at baseline, only 14 (22%) achieved target by 9 months. Conclusion: Poor lipid control occurred in two distinct patterns of undertreatment and inadequate treatment escalation. Achieving contemporary LDL-C targets in PAD will require practice changes to actively optimise therapy beyond statin prescription.

9:49 am

[Peri-Operative Adherence To Anticoagulation Protocols In Patients Undergoing Open Arterial Surgery At Lautoka Hospital](#) [Manisha Prakash](#)

Purpose Peri-operative anticoagulation is essential in reducing thrombotic complications following open arterial surgery. In Fiji, where open arterial procedures remain the primary treatment for advanced vascular disease, there is no formal local anticoagulation protocol. This study aimed to evaluate adherence to international peri-operative anticoagulation guidelines and its relationship with clinical outcomes at Lautoka Hospital. Methods A retrospective audit was conducted at Lautoka Hospital, Fiji, including all adults who underwent open arterial surgery between January 2025 and April 2026. Adherence was assessed against ESVS and SVS recommendations using electronic medical records and drug charts. Results A total of 108 patients were included. Overall adherence to peri-operative anticoagulation guidelines was 63.0% (68/108), while 37.0% (40/108) demonstrated protocol non-adherence. Adherence rates were 83.3% pre-operatively, 71.3% intra-operatively and 90.7% post-operatively. Surgeon preference was the leading cause of non-adherence (85.0%). At least one postoperative complication occurred in 33/40 (82.5%) non-adherent patients compared with 11/68 (16.2%) adherent patients. This association was statistically significant ($\chi^2 = 43.18$, $p < 0.001$). Protocol non-adherence was associated with increased odds of postoperative complications (OR 24.4, 95% CI 8.63-69.12). Following establishment of a vascular unit, overall adherence improved from 8.5% to 89.0%. Conclusion Peri-operative anticoagulation practices at Lautoka Hospital demonstrated moderate overall adherence to international guidelines, with most deviations attributable to practice variation. The establishment of a dedicated vascular unit was associated with significant improvement in

protocol adherence. Development of standardized local anticoagulation protocols may further improve patient outcomes and enhance the quality of vascular care in Fiji.

9:55 am

[Discussion](#)

10 September 2026

10:00 am - 10:30 am
Morning Tea

Catering - [Vascular Surgery](#), [Vascular Nursing](#)

10 September 2026

10:30 am - 12:30 pm
World Federation for Vascular Surgery

Scientific Session - [Vascular Surgery](#), [Vascular Nursing](#)

10:30 am

[World Federation of Vascular Societies and Global Vascular Companionship Update](#)
[Iman Bayat](#)

10:45 am

[Integration & Collaboration of International & National Societies – Why is this important and Where are we going?](#)
[Palma Shaw](#)

11:00 am

[Establishing Aortic Programs in Developing Countries](#)

11:15 am

[Revascularisation in Diabetic Foot Disease: Practical Decision-Making in Limb Salvage](#)
[Asha Malan](#)

11:30 am

[Update on Vascular Surgery in Fiji](#)

11:45 am

[Vascular surgical service in the Fiji Islands – a model in capacity building](#)
[David McClure](#)

For generations, RACS Fellows have been involved in providing volunteer surgical support to communities in the South Pacific. While the focus has generally been on service delivery, the broad aim has been to foster sustainable in-country health care delivery. The RACS Pacific Clinical Services Health Workforce Improvement Program currently sponsors Visiting Medical Teams (VMT) for volunteer service to 11 countries in the Asia-Pacific region. 2026 saw the first VMT for Vascular Surgery to Fiji. Unlike the service delivery model of Vascular VMTs to Nauru in previous years, the Fijian Vascular VMT had capacity building as its primary focus. This was made possible by the return of two Fijian Surgeons; following Vascular Surgery Fellowship training in Australia and New Zealand, respectively; to establish specialist Vascular Surgery Units in Suva and Lautoka. To provide the full breadth of Vascular Surgical care to their communities, these nascent Units have sought to •build a surgical team – with dedicated resident trainees - delivering open and endovascular surgery; •upskill local radiographers in Vascular ultrasound •upgrade podiatric and orthotic care to the overwhelming population of patients with diabetic foot disease. This paper describes the

outcome of this year's RACS Vascular VMT to Fiji, and the ongoing mentorship that exists for our Fijian Vascular Surgery colleagues – through personal contact, with previous training relationships, and through the broader support network that exists in Global Vascular Companionship. A scholarship program in vascular ultrasound training has been established, with its first award recipient to complete the program in September. Future mission trips to Fiji are planned to include podiatric and orthotic educative support. Our Fijian Vascular Surgeons are playing an integral role in “Shaping the Future of Vascular Surgery” for the people of the Fiji Islands. Their support in this endeavour is our collective responsibility.

12:00 pm

[The Rutherford Lecture: Management of carotid artery disease for stroke treatment and prevention: an evolutionary tale](#)
[Wesley Moore](#)

10 September 2026

12:30 pm - 1:30 pm
Lunch

Catering - [Vascular Surgery](#), [Vascular Nursing](#)

10 September 2026

12:45 pm - 1:15 pm
Medtronic Lunch Symposium: Carotid Innovations

Scientific Session - [Vascular Surgery](#)

10 September 2026

1:30 pm - 3:00 pm
Vascular Imaging & Surveillance

Scientific Session - [Vascular Surgery](#), [Vascular Nursing](#)

1:30 pm

[Duplex Ultrasound Surveillance After Endovascular Therapy for Peripheral Artery Disease: An Australian and New Zealand Study](#)
[Thomas Warburton](#)

Purpose: Current practice guidelines lack consensus on optimal surveillance strategies following endovascular interventions for peripheral artery disease (PAD). This study evaluated surveillance practices among vascular surgeons in Australia and New Zealand (ANZ), focusing on duplex ultrasound (DUS) use and factors influencing surveillance protocols. Methodology: All consultant vascular surgeons in the Australian and New Zealand Society for Vascular Surgery were invited to participate in an online survey examining demographics, practice characteristics, surveillance protocols after endovascular interventions, and decision-making regarding surveillance and reintervention. Results: Of 266 surgeons, 73 responded (27%). Respondents were predominantly experienced (77% with ≥ 10 years practice) and worked in teaching hospitals (88%). Most performed an initial post-procedural DUS (89%) and ongoing routine DUS surveillance (83%). Surveillance protocols varied considerably, with 67% tailoring intervals based on patient/lesion factors rather than predetermined schedules. Practice variation was independent of surgeon experience, practice setting, or geography. All surveyed chronic limb-threatening ischaemia patients, versus 93% for intermittent

claudication. Reintervention thresholds varied by anatomy: 58% required symptoms before intervening for infrapopliteal disease compared to 15% for aortoiliac disease. Most surgeons (82%) acknowledged significant uncertainty regarding optimal surveillance strategies. Conclusion: Substantial practice variation exists in post-endovascular surveillance among ANZ vascular surgeons. While most employ DUS surveillance, frequency, duration, and intervention thresholds differ markedly. These findings highlight the need for prospective studies to determine optimal surveillance protocols balancing clinical outcomes with resource utilisation.

1:38 pm

[Renal artery aneurysm surveillance: a multi-centre perspective](#)

[Amnshumaan Kishore](#)

Surveillance protocols for renal artery aneurysms (RAAs) vary considerably between institutions, with limited evidence to guide optimal imaging intervals and modalities. As the widespread adoption of advanced three-dimensional imaging techniques has increased the incidental detection of RAAs has drastically increased. While generally accepted to be indolent, the natural history of many RAAs remains poorly defined. Despite this, the life-threatening risk of rupture makes establishing safe, effective, and economical surveillance strategies of utmost importance. A retrospective review was performed of patients within Metro North Health who were followed up in the nurse led surveillance clinic. Patients were identified from all the patients with renal artery aneurysms under surveillance from the conception of the clinic in 2014. Inclusion criteria required patients to have undergone at least two surveillance scans. Demographic, clinical, and imaging data were collected and analysed. A total of 41 patients met the inclusion criteria and were included in the study. Aneurysm size ranged from 8-24mm, with a mean diameter at the commencement of surveillance of 13.4mm. The average duration of surveillance was 1409 days. During surveillance, aneurysms demonstrated measurable growth, corresponding to an average growth rate of -0.55 ± 1.73 mm per year. The majority of aneurysms remained stable throughout the surveillance period. No aneurysm ruptures were observed, and no patients underwent intervention during follow-up. In this cohort, renal artery aneurysms minimal growth, with most lesions remaining stable during the study period. Furthermore, this study highlights the significant discrepancy in measurement between different imaging modalities. These findings support a conservative surveillance regime. Further studies with larger patient populations and longer follow-up are required to better define the natural history of RAAs and inform optimal surveillance strategies.

1:46 pm

[Discussion](#)

1:51 pm

[Open Revascularisation Delivers a Greater Improvement in Pedal Acceleration Time Compared to Endovascular Revascularisation](#)

[Charles Buchanan](#)

Objective: Pedal acceleration time (PAT) is a novel sonographic method for assessing foot perfusion in peripheral arterial disease (PAD), which has been shown to correlate with wound healing and amputation-free survival. This study aimed to assess the response of PAT to open compared to endovascular revascularisation approaches. Secondary outcomes were major limb amputation (MLA) and death. Methods: This was a retrospective study that included patients who underwent a revascularisation procedure for PAD of any severity from 2021-2024 at a single tertiary-centre. PAT were obtained by trained sonographers prior to and after the revascularisation procedure. Data was collected on disease severity, renal function, diabetes, MLA, and mortality. Data was analysed using t tests and reported as % or mean $\pm$ SD. Results: There were a total of 1,111 revascularisation procedures over the study period, of whom 463 patients had pre- and post-PAT measurements and were included. Average age was 71.4 ± 10.3 yr, 66.3% diabetic, creatinine 162.9 ± 203.1 μ mol/L and median Rutherford class 5. PAT improved with revascularisation in all groups, open (n=79) pre 241.6 ± 62.0 vs post 120.0 ± 42.3 , endovascular (n=356) pre 192.3 ± 65.0 vs post 138.5 ± 48.1 , hybrid (n=28) pre 235.2 ± 51.3 vs post 146.4 ± 45.6 , all $P < 0.0001$. Open revascularisation was associated with a greater change in PAT compared to endovascular revascularisation, change in PAT with open 109.0 ± 66.9 vs endovascular 53.1 ± 66.9 , $P < 0.0001$. Open revascularisation was associated with lower rates of MLA and 1yr mortality, 8.9% vs 14.0% and 5.0% vs 20.8%, respectively. Conclusion: This study showed that open revascularisation resulted in the greatest improvement in PAT. Future studies should seek to validate these findings in larger cohorts and assess the impact of disease severity on PAT.

1:57 pm

[Hand acceleration time: A novel tool for assessing upper limb perfusion](#)

[Philip Allan](#)

Purpose Assessment of upper limb ischaemia is primarily clinical, with current non-invasive methods of

quantifying upper limb perfusion (e.g. oxygen saturation or digital-pressures) being non-standardised. Hand acceleration times (HATS) is a novel non-invasive ultrasound based perfusion measurement that could aid in the diagnosis of upper limb ischaemia, however there has been limited characterisation of it in the literature. This study sought to compare HATS values in a patients with or without sonographic evidence of arterial disease. Methodology This was a single-centre prospective study of patients who were referred to Vascular Surgery with clinical concern for upper limb ischaemia or with a arteriovenous fistula issue, and who underwent HATS measurement. Patients were categorised into those that had a sonographic evidence of arterial disease (PAD; stenosis >50% or occlusion), and those that didn't. Demographic, comorbidity, and clinical presentation data was collected. Data was analysed using t- and χ^2 tests and is expressed as mean $\pm$ SD or %. Results 28 patients were included, 15 (59 $\pm$ 18y, 47% male) with PAD and 13 (57 $\pm$ 21y, 62% male) without. There was no difference in comorbidities between groups, except for higher antiplatelet use in the PAD group (60 vs 23%, p=0.049). Across the cohort, rest pain was the most common presentation (57.1%), followed by tissue loss (17.9%), then claudication (10.7%). There was no difference in the proportion of patients presenting with each symptom between groups. HATS was significantly worse (higher) in the PAD group 162ms vs 83ms (p=0.0097). In a subset of five patients with digital tissue loss, HATS values were the same in digits with and without tissue loss (128 vs 132ms). Conclusion HATS measurement appears to correspond appropriately to stenotic or occlusive arterial disease, and may be a sensitive diagnostic tool for upper limb ischaemia. Further work is required to validate HATS against current upper limb perfusion measures.

2:03 pm

[Discussion](#)

2:08 pm

[Examining the pathophysiological importance of atherosclerotic and non-atherosclerotic arterial wall hypoxia with \[18F\]Fluoromisonidazole](#)
[Nishath Altaf](#)

2:14 pm

[Aortic calcification as an imaging surrogate marker in predicting major adverse cardiovascular events](#)
[Chinmay Sharma](#)

2:20 pm

[Psoas muscle density correlates better with age-related sarcopenia and operative risk than psoas muscle area](#)
[Louis Scarrold](#)

2:26 pm

[Discussion](#)

10 September 2026

3:00 pm - 3:30 pm
Afternoon Tea

Catering - [Vascular Nursing](#), [Vascular Surgery](#)

10 September 2026

3:30 pm - 5:30 pm
Diabetic Foot disease, Limb Salvage & Multi-Disciplinary Team Approach

Scientific Session - [Vascular Surgery](#), [Vascular Nursing](#)

3:30 pm

[Closing the Gap? Disparities in Presentation and Outcomes of Diabetic Foot Disease in Aboriginal and Torres Strait Islander Patients](#)

[Myrna Ishak](#)

Purpose First Nations Aboriginal and Torres Strait Islander people have a higher prevalence of diabetic foot disease and consequent major limb amputations in Australia. Our aim is to examine the outcomes of Aboriginal and Torres Strait Islander patients undergoing toe amputation for diabetic foot disease (DFD) in comparison to others and identify contributing risk factors for less favourable outcomes. Methodology A retrospective cohort study was conducted in Cairns Hospital amongst inpatients of the vascular surgery unit who were admitted for management of DFD from 1st of January 2015 to 31st of December 2024. Primary outcomes were requirement of further foot debridement and/or minor amputations following index procedure and subsequent ipsilateral major limb amputation. Secondary outcomes included all-cause post-operative mortality and perioperative incidence of MACE. Results 231 patients were included over a period of 10 years. Aboriginal and Torres Strait Islander residents represent 12.6% of the Cairns and Hinterland Hospital and Health Service (CHHHS) population. In our cohort, 48.1% were of this background. In comparison to other patients, Aboriginal and Torres Strait Islanders had a significantly lower median age of presentation to hospital ($p = 0.016$), significantly higher likelihood of requiring further digital amputation/s ($p = 0.002$), and a significantly shorter duration of time before re-presentation for a recurrent minor amputation ($p < 0.02$) following the index minor amputation. This affected males and females almost equally (55.8% and 44.2%), in contrast to males being more affected in other patient groups. Conclusion This is one of the largest representations of Aboriginal and Torres Strait Islander patients in current Australian literature looking at outcomes following minor amputations in patients with DFD. There is a notable over-representation and significant discrepancy in outcomes among Aboriginal and Torres Strait Islander peoples in comparison to others with DFD.

3:38 pm

[Challenges of limb salvage in rural and remote areas of Australia and New Zealand](#)

[Peta Tehan](#)

3:48 pm

[The functionality of high-density lipoproteins is impaired in people with diabetes that require minor amputations](#)

[Zahra Lotfollahi](#)

Background: High-density lipoprotein (HDL) functionality is emerging as a novel predictor of disease outcomes. The role of HDL functionality in patients with diabetes-related amputations is not explored. We aimed to assess changes in HDL functionality in people with diabetes who had minor amputations and to determine the relationship between HDL functionality and wound closure. Methods: Thirty patients with diabetes (DM) and eleven without diabetes (Non-DM) undergoing minor amputations were recruited. Blood was collected at baseline, 1-month and 6-months post-amputation, and from 20 healthy gender- and age-matched control participants. HDL was isolated from plasma and functionality markers of macrophage cholesterol efflux, and anti-inflammatory and pro-angiogenic capacities in endothelial cells were assessed. Results: HDL-c levels positively correlated with wound closure ($r=0.44$, $P<0.05$). Cholesterol efflux capacity of DM HDL was reduced at 1-month post-amputation (-44% vs. Non-DM HDL, $P<0.05$). In response to an inflammatory stimulus, cells treated with DM HDL had elevated levels of CX3CL1 (+92%), CCL2 (+49%), VCAM1 (+67%) and ICAM1 (+58%) (vs. Non-DM HDL, $P<0.05$). The capacity of cells to form tubules reduced linearly with time following DM HDL treatment ($P<0.05$), concomitant with reduced VEGFA expression (-47% vs Non-DM HDL, $P<0.05$). Furthermore, cells treated with HDL from participants with delayed wound closure (<60% at 1-month post-amputation) exhibited reduced VEGFA expression (-40%) and increased RELA expression (+50%, both $P<0.05$). Conclusion: HDL functionality could be used to identify patients that may benefit from early therapeutic intervention, guiding wound care management approaches.

3:54 pm

[Discussion](#)

4:04 pm

[Functional and Clinical Outcomes of Hallux and Lesser Digit Amputations in Diabetic Foot Disease](#)

[Myrna Ishak](#)

Purpose Digital amputations are frequently used in the treatment of diabetic foot ulcers and infections. It is widely believed that hallux amputations disrupt gait patterns and foot anatomy, leading to poor outcomes compared to lesser toe amputations. However, there is minimal evidence to support this idea from research comparing the short and long-term outcomes of patients undergoing hallux versus lesser toe amputations. Additionally, there are only a few studies comparing outcomes of transphalangeal with transmetatarsal

amputations. The aim of our study was to compare the following outcomes; ipsilateral further digital amputations, major amputations, major adverse cardiovascular events (MACE), and death. Methodology A retrospective cohort study was conducted amongst vascular surgery inpatients of Cairns Hospital from January 2015 to December 2024. Patients with a diagnosis of diabetes mellitus undergoing single hallux or lesser digit amputation were included. Those undergoing digital amputation for pathology other than diabetic foot disease were excluded. Outcomes were examined using Cox-proportional hazard analyses. Results Of the 480 patients that were included, 207 underwent hallux amputation and 273 underwent a lesser toe amputation. A significant proportion of hallux amputations were performed as an emergency procedure ($p = 0.014$). There was no significant difference between the proportion of patients requiring further digital amputation or ipsilateral major limb amputation. Time to an ipsilateral further digital amputation was significantly shorter in the hallux amputation group ($p = 0.021$). There was no significant difference between incidence of MACE or post-operative death between the two groups. Conclusion Minor diabetic foot amputations are associated with risk of repeat digital amputation, MALE, MACE, death. There are comparable rates of these consequences amongst those undergoing hallux or lesser toe amputation; one is not “safer” than another.

4:10 pm

[Outcomes of the use of PolyNovo Biodegradable Temporising Matrix \(BTM\) and MTX in diabetic foot wounds](#)

[James Kellie](#)

4:16 pm

[Biodegradable Temporising Matrix in High-Risk Diabetic Foot Wounds: Who Benefits Most?](#)

[Chui Foong Ong](#)

Purpose Complex diabetic foot wounds (DFUs) with exposed bone, tendon, or extensive soft tissue loss remain a major challenge in limb salvage. Biodegradable Temporising Matrix (BTM) is an emerging dermal substitute for wound bed reconstruction; however, predictors of success in high-risk diabetic foot populations remain poorly defined. This study evaluates outcomes following BTM and identifies patient and wound factors associated with successful wound healing. Methodology A prospective observational study of BTM cases from April 2024 to June 2026 was conducted at a single tertiary Australian Diabetic Foot Service. Twenty-three patients (24 limbs) were included. Baseline demographics, wound characteristics, Wifl stage, dialysis dependence, and osteomyelitis were recorded. Outcomes included complete wound healing, amputation, mortality, length of hospital stay (LOS), and readmissions. Results Mean age was 66 years (54–80) with median follow-up of 29 weeks (IQR 0–43). Mean LOS was 25 days (IQR 3–66). Complete wound healing occurred in 11 limbs (45.8%) at a median of 29 weeks. Most achieved graft integration, with 2 required split-skin graft. Complications included graft loss in 6 limbs, minor amputation in 5, and major amputation in 3. Three deaths (12%) occurred, all unrelated to the procedure. Readmissions occurred in 14 cases, primarily for wound management or further intervention. Wifl stage 3–4, osteomyelitis, and dialysis dependence were associated with poorer outcomes, though dialysis numbers were small. Wifl stage was most consistently associated with delayed wound healing, higher LOS and readmissions. Conclusion BTM is a useful adjunct in selected complex DFUs, achieving moderate wound healing. Outcomes are primarily driven by limb threat severity and infection burden, particularly Wifl stage and osteomyelitis. Resource utilisation remains substantial, with prolonged admission and readmissions. Careful patient selection is essential to optimise limb salvage and reduce treatment burden.

4:22 pm

[Revisiting Limb Salvage in Diabetic Foot Osteomyelitis: A Systematic Review of The Role of Antibiotic-Impregnated Bioresorbable Bone Fillers](#)

[Haywood Yeung](#)

4:28 pm

[Discussion](#)

4:38 pm

[The Impact of Cognition, Concordance and Context on DFU Healing](#)

[Kathleen Finlayson](#)

4:44 pm

[Composite Cardiovascular Risk Improved with Multidisciplinary Team Care of Patients with Peripheral Artery Disease in the TEAM-PAD Trial.](#)

[David Savoian](#)

Purpose: The high cardiovascular mortality in Peripheral Artery Disease (PAD) means secondary prevention

needs accurate risk assessment and monitoring. The TEAM-PAD randomised trial compared reduction in cardiovascular risk in multidisciplinary team (MDT) care to usual care using the SMART-REACH score. We assessed 9-month outcomes and explored if treatment effects were also measurable using an Australian risk calculator (AusCVD). Methodology: The primary endpoint in the TEAM-PAD trial was change in cardiovascular risk from baseline to 9-months, assessed using SMART-REACH. AusCVD scores were analysed for exploratory comparison. Between group differences in risk change (MDT vs usual care) were assessed and predictors of improvement were evaluated by correlation and logistic regression. Results: A total of 130 patients were included (MDT n=66; standard care n=64). MDT significantly improved cardiovascular risk as measured by SMART-REACH, with a mean between group difference of 3.8 (p=0.018), but not as measured by AusCVD (p=0.457). Overall, there was no significant risk change across the cohort for either SMART-REACH (46.9 vs 48.2; p=0.066) or AusCVD (16.3 vs 17.4; p=0.152). SMART-REACH and AusCVD change scores were weakly correlated (p=0.084, p=0.348). SMART-REACH improvement was associated with higher baseline LDL (OR 1.7; p=0.014), while current smoking reduced likelihood of improvement (OR 0.3; p=0.025). Improvement in AusCVD measured risk was associated with CLTI (OR 2.5; p=0.03), weekly exercise (OR 2.7; p=0.02), and higher baseline SBP (OR 1.0; p=0.03). Conclusion: At 9-months, MDT care improved cardiovascular risk for PAD patients, as measured by SMART-REACH, and despite no overall cohort change, we demonstrated that risk can be modified with structured care. The absence of detectable change using AusCVD suggests differences in treatment sensitivity. Risk scores must support both risk stratification and monitoring, needing further validation in clinical use.

4:50 pm

[Title: Redefining Responsibility in PAD Care: Australian Doctors' Perspectives on Multidisciplinary Management](#)
[Miriam Wiersma](#)

Purpose: Long-term outcomes of peripheral artery disease (PAD) are driven more by cardiovascular risk than adverse limb events. Although effective risk reduction therapies exist, their implementation is inconsistent. Multidisciplinary (MDT) care improves outcomes, but in vascular surgery, MDTs focus primarily on surgical decisions with limited input into cardiovascular risk prevention. The TEAM-PAD RCT evaluated whether a virtual MDT improved guideline-based secondary prevention, while an embedded early-phase implementation study explored clinician perspectives on the MDT model, including barriers and facilitators. Methodology: Qualitative semi-structured interviews with 14 MDT clinicians (6 vascular surgeons, 2 endocrinologists, 2 drug and alcohol clinicians, a nephrologist, cardiologist, geriatrician and pharmacist) were conducted. Data were analysed using thematic analysis and mapped to the RE-AIM framework. Results: Perceived facilitators included clear communication, actionable recommendations for general practitioners (GPs), and improvements in patient care. The main barrier was inconsistent GP uptake of MDT recommendations, partly due to communication gaps. Clinicians expressed uncertainty about who should be responsible for cardiovascular risk management. Despite the MDT not directly involving GPs, many still felt they ought to be primarily responsible for cardiovascular risk management. However, hospital-based clinicians recognised constraints in primary care, including limited time, resources, and variable expertise. Conclusion: While there is consensus that cardiovascular risk management should occur in primary care, its delivery remains suboptimal for patients with PAD. A gap in ownership of preventive care persists. Effective MDT implementation requires clearer delineation of responsibilities, with vascular surgeons taking a more proactive role in cardiovascular risk prevention.

4:56 pm

[A Dedicated Vascular Home Hospital Pathway Safely Delivers Complex Limb Preservation Care While Increasing Acute Surgical Bed Capacity](#)
[Tishanthan Pathmarajah](#)

Purpose: Patients with diabetic foot disease frequently require prolonged inpatient admission for intravenous antimicrobial therapy, wound management and multidisciplinary care. We evaluated the clinical outcomes, resource utilisation, financial impact and service capacity of a dedicated Vascular Home Hospital (HH) pathway within a tertiary vascular surgery service. Methodology: A retrospective review was undertaken of all patients managed through the Royal Perth Vascular HH pathway between March and June 2026. Patient demographics, HH length of stay (LOS), readmission rates, bed occupancy and estimated cost implications were analysed. Results: Twenty-four vascular episodes of care were identified. Most patients were managed for diabetic foot complications, osteomyelitis and complex wounds requiring prolonged treatment following inpatient vascular assessment and intervention. Median HH LOS was 10.6 days (mean 15.2), generating 366 HH bed-days over four months, equivalent to the continuous availability of three additional inpatient beds. Three patients (12.5%) required readmission within 28 days; however, none were related to the index vascular diagnosis. Inpatient bed occupancy remained high (81–92%), comparable to the preceding 12 months, facilitating treatment of additional patients without increasing bed numbers. Based on activity-based costing, HH care reduced daily expenditure by 9.8% compared with inpatient

management (\$1,286 vs \$1,425/day), generating estimated savings of \$50,874. Conclusion: A dedicated vascular HH pathway provides a safe and effective model for managing selected limb preservation and complex wound patients. Beyond direct cost savings, its principal benefit was increased service capacity, functioning as a virtual expansion of vascular ward capacity without increasing physical bed numbers. Expansion of vascular-specific HH services may help meet growing demand on tertiary vascular services while preserving access to acute inpatient care.

5:02 pm

[An observational study on the extent of peripheral arterial disease in the Fijian lower limb amputee.](#)
[Shahzad Sadiq](#)

Purpose In the Fiji Islands the number of major lower limb amputations being performed has reached epidemic proportions. At the Colonial War Memorial Hospital (CWMH) this number has exceeded 300 each year over the past decade. The question has been asked of whether pre-emptive treatment of lower limb artery disease by endovascular intervention might have a role. The profile of lower limb arterial disease in the Fijian population is unknown, and this study was undertaken to define such need. **Methodology** A cross-sectional study was conducted at CWMH, Suva, Fiji. Adults with a prior unilateral lower-limb amputation underwent duplex ultrasound of the contralateral limb from the common femoral artery to the ankle. PAD was defined as $\geq 50\%$ stenosis (peak systolic velocity ratio ≥ 2.0) or occlusion. Disease was classified as femoral–popliteal, tibial, or combined. Lesions were designated "consider for intervention" when judged anatomically suitable for endovascular therapy within the local service context. **Results** Forty-eight adults were enrolled (mean age 58 years; 97.9% with diabetes). Most index amputations were sepsis-related below-knee procedures within six months of assessment. Clinically, 27.1% of contralateral limbs had ulceration and only 41.7% had normal sensation. Duplex ultrasound demonstrated PAD in 54.2%; tibial-only disease accounted for 31.3%, femoral–popliteal-only for 4.2%, and combined disease for 18.8%. Approximately half of PAD-positive limbs were considered potentially amenable to endovascular intervention. **Conclusion** Amputation rates for diabetic foot disease are substantially higher in centres across the South Pacific than those observed in high income countries. The identification of remedial lower-limb arterial disease in this cohort of Fijian amputees has provided the impetus to develop an endovascular service in the country, managed by local surgeons under the mentorship of Australian vascular surgical colleagues.

5:08 pm

[Discussion](#)

3:30 pm - 5:00 pm
Vascular Ultrasound Workshop

Workshop - [Vascular Surgery](#), [Vascular Nursing](#)

10 September 2026

5:30 pm - 6:30 pm
Welcome Reception

Cocktail - [Vascular Nursing](#), [Vascular Surgery](#)

10 September 2026

7:00 pm - 10:30 pm
Trainees Dinner

Speciality Dinner - [Vascular Surgery](#)

11 September 2026

7:00 am - 8:20 am
Women in Vascular Surgery Breakfast

Breakfast Session - [Vascular Surgery](#)

11 September 2026

8:30 am - 10:30 am
Peaks, Pathways & Possibilities

Scientific Session - [Vascular Nursing](#)

Focus: Policy, Equity, Research & Framework

8:30 am - 10:00 am
Venous Disease: DVT & PE

Scientific Session - [Vascular Surgery](#)

8:30 am

[Two-Year Outcomes of Mechanical Thrombectomy for Iliofemoral versus Isolated Femoropopliteal Deep Vein Thrombosis: Results From the CLOUT Study](#)
[Rajesh Malik](#)

Purpose: To compare outcomes of contemporary mechanical thrombectomy for iliofemoral deep vein thrombosis (IF-DVT) vs isolated femoropopliteal DVT (iFP-DVT). Methodology: The CLOUT study (NCT03575364) evaluated mechanical thrombectomy with the ClotTriever system (Inari, Irvine, CA, US) for proximal lower extremity DVT. Here, outcomes were assessed after grouping subjects by anatomical disease location. The primary effectiveness endpoint was $\geq 75\%$ postprocedural thrombus removal based on independently adjudicated Marder scores. Additional outcomes, including postthrombotic syndrome (PTS) by Villalta score, were collected through 2-year follow-up. Results: After grouping by DVT location, IF-DVT was present in 389 (78.6%) limbs from 379 subjects, and iFP-DVT was present in the remaining 106 (21.4%) limbs from 105 subjects. In the IF-DVT group, there was a larger proportion of female subjects (53.3% vs 41.6%, $P=.0436$), but no other significant differences in baseline characteristics were observed. A comparable proportion of limbs in each cohort achieved the primary endpoint of $\geq 75\%$ thrombus removal (90.5% vs 93.4%, $P=.4415$). Comparing the IF-DVT and iFP-DVT cohorts, treated limbs demonstrated similar improvements in patency from baseline (18.4% vs 11.8%, $P=.1924$) through 2-year follow-up (94.9% vs 90.0%, $P=.2699$). There were no significant differences in Villalta score between the IF-DVT and iFP-DVT groups at any study visit, improving from baseline (median score 9.0 vs 10.0, $P=.2732$) through 2-year follow-up (median score 1.0 vs 2.0, $P=.7186$). At the 2-year visit, the distribution of PTS severity was not significantly different in the IF-DVT vs iFP-DVT cohorts (none: 80.6% vs 81.4%, mild: 13.6% vs 8.5%, moderate: 3.7% vs 6.8%, severe: 2.1% vs 3.4%; $P=.4695$). Conclusion: Mechanical thrombectomy achieved similar outcomes in IF-DVT and iFP-DVT. Additional research is warranted to better understand the benefits and limitations of this intervention for patients with iFP-DVT.

8:38 am

[How Expensive is a Swollen Leg? – A single-centre retrospective review and cost analysis of deep venous thrombosis duplex studies](#)
[Michael Na](#)

Purpose Duplex ultrasound presents a quick, non-invasive investigation for deep venous thrombosis (DVT), and its use has expanded over the years with the prevalence of vascular ultrasound laboratories. We assessed the volume of requests, rates of positive scans and surgical intervention at our centre with a cost-

analysis to characterise the overall impact on the healthcare system. Methodology We conducted a retrospective cohort analysis of all DVT exclusion requests at our institution from January to May 2026. The primary outcome was scan demonstrating acute DVT, with secondary outcome of referral for consideration of surgery. Results A total of 613 scans were conducted over 5 months, with 350 for inpatients, 194 outpatients and 69 in the emergency department. There were 213 unilateral lower limb, 256 bilateral lower limb and 144 upper limb (unilateral) requests. 99 noted previous DVT (16.3%), 56 had diagnosed pulmonary embolism (PE) (9.1%), and 54 noted recent venous cannulation. 94 scans reported acute DVTs (29 upper and 65 lower limb, 15.3%), with 38 of those in patients with PE. 40 out of 59 acute DVTs involving femoral or upper limb veins were referred for surgical opinion. Notably, 38 requests were for “screening” (6.2% of total requests), 13 of which found a DVT, and 151 requests had no significant clinical information with 19 finding an acute DVT (12.6%). With the current Medicare schedule fee for acute DVT scan being \$194.65 and up to 95% rebate for a bulk billed scan, we estimated an overall cost over 110,000AUD over 5 months to Medicare for 5 months of DVT exclusions studies in our centre. Conclusion DVT exclusion duplexes at our institution demonstrated appropriate diagnostic yield (15.3% positive rate), and 42.6% of those with acute DVT were also referred for surgical opinion. Whilst DVT exclusion studies do have a significant cost to the taxpayer, their use at our centre does seem appropriate in the context of a significant pathology.

8:44 am

[Discussion](#)

8:52 am

[Results From the Completed FLASH Study of Large-Bore Mechanical Thrombectomy for Acute Pulmonary Embolism](#)

[Rajesh Malik](#)

Purpose: To present the outcomes of large-bore mechanical thrombectomy (LBMT) for acute pulmonary embolism (PE) from the combined US and European cohorts of the FLASH study. Methodology: FLASH (NCT03761173) prospectively enrolled real-world subjects treated with the FlowTrier system (Inari, Irvine, CA, US) for intermediate-risk or high-risk PE. The composite primary endpoint consisted of independently adjudicated major adverse events (AEs) comprising major bleeding and device-related mortality through 48 hours and intraprocedural device-related or procedure-related AEs. Severe dyspnea was defined as a modified Medical Research Council score of 3 or 4. Subjects were followed for 6 months. Results: The analysis population included 999 subjects enrolled across 69 sites. Mean age was 61.6±14.3 years, and 453 (45.3%) subjects were female. The stratification by PE risk was 14.3% high risk, 72.0% intermediate-high risk, 6.5% intermediate-low risk, and 7.1% intermediate risk without further classification. Immediately after thrombectomy, mean pulmonary artery pressure improved from 32.6±8.8 to 25.0±8.6 mmHg (-22.7% for paired values, P<.0001). Thrombectomy time was 49.8±35.4 minutes, and adjunctive therapy was used in 22 (2.2%) cases. Twenty-four (2.4%) subjects met the primary endpoint, 0 with device-related mortalities, 17 (1.7%) with major bleeds, and 8 (0.8%) with intraprocedural AEs related to the device or procedure. All-cause mortality rates at 48 hours, 30 days, and study exit were 0.6%, 1.8%, and 5.6%, respectively. The proportion of subjects with severe dyspnea improved from 70.9% at baseline to 16.2% (P<.0001) at the 48-hour visit and continued improving to 3.0% (P<.0001) at the 6-month visit. There were low rates of chronic thromboembolic pulmonary hypertension (1.2%) and post-PE syndrome (1.9%) at 6-month follow-up. Conclusion: Data from the FLASH study of acute PE indicate that LBMT is safe and associated with favorable acute and long-term outcomes.

9:00 am

[Closing the Gap: Mechanical Thrombectomy for Acute Pulmonary Embolism in Regional and Rural North Queensland, Australia](#)

[David Sun](#)

Objective To evaluate the feasibility and early outcomes of large-bore mechanical thrombectomy for intermediate-high and high-risk pulmonary embolism (PE) in a regional Australian tertiary referral centre. Methods A retrospective cohort study was conducted at a regional tertiary hospital in North Queensland between January 2022 and June 2025. Consecutive patients undergoing mechanical thrombectomy following multidisciplinary Pulmonary Embolism Response Team (PERT) evaluation were included. Demographic, procedural, and short-term clinical outcomes were analysed descriptively. Results Twenty-three patients underwent mechanical thrombectomy. Technical success was achieved in all cases (100%) with no immediate procedural complications. Eleven patients (47.8%) required post-procedural intensive care unit admission. Mean oxygenation saturation increased modestly following intervention (94.7% to 96.4%), although interpretation is limited by heterogeneity in oxygen support. Among 17 patients with follow-up imaging within 48 hours, 6 (35.3%) demonstrated reduction in right ventricular to left ventricular (RV/LV) ratio to < 0.9. The mean hospital length of stay was 17.9 ± 21.6 days (median 9 days). Thirty-day mortality was 8.7%. Conclusions Large-bore mechanical thrombectomy for acute PE was feasible and safely

delivered in a regional Australian centre, with acceptable short-term outcomes in a high-risk cohort. These findings support the potential for appropriately resourced regional centres to provide advanced interventional PE care.

9:06 am

[Discussion](#)

9:16 am

[Durability of Prosthetic Venous Grafts After Major Caval and Iliocaval Reconstruction](#)

[Keely Gardiner](#)

Purpose: Major venous resection and reconstruction are frequently required during retroperitoneal sarcoma (RPS) surgery for complete oncological resection. However, concerns remain regarding long-term prosthetic venous graft durability, with limited available data. This study evaluated graft patency and reintervention following venous reconstruction during RPS resection. Methodology: All patients undergoing major venous reconstruction during RPS surgery at Sir Charles Gairdner Hospital, Western Australia, between January 2010 and June 2025 were included. Demographic, operative, and follow-up data were collected retrospectively. Primary outcomes were primary graft patency and graft-related reintervention. Results: 36 venous reconstructions were performed. IVC reconstruction was most common (n=26), followed by iliocaval (n=5) and iliac vein reconstruction (n=5). Polytetrafluoroethylene was the predominant conduit (88.9%). Median caval graft diameter was 20 mm (16-24 mm). Over a median follow-up of 35.8 months, five graft occlusions occurred (13.9%), four (80%) within six weeks postoperatively. Kaplan-Meier estimated freedom from graft occlusion was 88.7% at 1 and 3 years (95% CI 78.9–99.8%), and 79.8% at 5 years (95% CI 63.0–100%). Iliocaval reconstructions had a higher observed occlusion rate than isolated IVC reconstruction (40% vs 11.5%), although this did not reach statistical significance. Four graft-related reinterventions were performed (11.1%), two for thrombosis and two for graft kinking. Discharge anticoagulation included rivaroxaban (n=18), apixaban (n=12) and warfarin (n=2), with no association with graft occlusion. Conclusion: Major venous reconstruction during RPS surgery demonstrates favourable long-term durability, with approximately 80% primary patency at five years. Most occlusions occurred within six weeks postoperatively, indicating an early period of increased risk. These findings highlight early thrombosis prevention as a key target for future research.

9:22 am

[Venous TOS thrombolysis and rib resection strategies: Lessons learned over 20 years](#)

[Jason Lee](#)

9:30 am

[Patient reported outcomes following decompression for Primary Subclavian Venous Thrombosis](#)

[Nishanth Wood](#)

Purpose: Primary subclavian venous thrombosis is an uncommon condition that usually affects young and active people. Anticoagulation alone without addressing the underlying pathology may result in post-thrombotic syndrome (PTS) in 40-50% of patients. Decompression with a first rib resection and an endovenous treatment to restore vein patency is recommended to prevent PTS. While the treatment is safer, there is little published data on functional and patient-reported outcomes in this group. Methodology: Patients between February 2020 to May 2026 presenting with primary subclavian venous thrombosis were recruited prospectively. Patients completed the DASH questionnaire and a validated thoracic outlet syndrome survey. All patients had the first rib removed via an infraclavicular incision with an endovascular venous procedure to address the thrombosis. The primary outcome was patient-reported symptoms using validated tools, and the secondary outcome was the clinical result according to Derkash classification. Results: 19 patients were included and 7 were females. The median (range) age was 27 (16-54). The length of the index presentation hospital stay was 4 days, and there were no returns to theatres. 18 patients had a patent vein during follow-up. There was an overall improvement in the DASH score with a 15.8-point difference. 16 patients reported "good" to "excellent" improvement using the Derkash classification. The thoracic outlet syndrome survey improved in all categories (pain, sports, work, emotions, lifestyle) between two and nine points per domain. Conclusion: Patient reported outcomes following endovenous therapy and first rib resection are good, with improvements observed from baseline. Longer-term functional outcomes require further reporting in this young group of patients.

9:36 am

[Discussion](#)

11 September 2026

10:00 am - 10:30 am
Morning Tea

Catering - [Vascular Nursing](#), [Vascular Surgery](#)

11 September 2026

10:30 am - 12:30 pm
Kidneys, Reno-Vascular Access & the Environment

Scientific Session - [Vascular Surgery](#)

10:30 am

[Two-Year Clinical Outcomes from the WRAPSODY® Arteriovenous Access Efficacy \(WAVE\) Trial](#)
[Manar Khashram](#)

10:38 am

[Central Venous Stenosis: Pushing the Boundaries](#)

10:46 am

[Discussion](#)

10:56 am

[IMPART-TRIAL: Negative pressure wound therapy versus standard dressings for incision management after renal transplant: a multicentre, partially blinded randomised controlled trial](#)
[Michael Na](#)

11:02 am

[Renal Access and Patient Care: Delays to Arteriovenous Fistula Haemodialysis](#)
[Gabrielle Stratford](#)

11:08 am

[Outcomes of a Single Centre Regional Renal Physician-led Dialysis Access Clinic: A Comparative Study](#)
[Nima Iranpour](#)

Introduction: Traditionally, renal access clinics have been vascular-led due to the specialist nature of the definitive procedure; however, some rural centres have experimented with a physician-led model as part of a multi-disciplinary approach. This study investigates the impact of rural physician-led renal clinics on patient outcomes, particularly focusing on arteriovenous fistula (AVF) or graft (AVG) at the first session of haemodialysis. The analysis compares outcomes across rural and urban New South Wales (NSW) centres to determine the effectiveness of physician-led care in improving vascular access for dialysis patients. Method: Data was extracted from the Australia and New Zealand Dialysis and Transplant Registry, covering 2020-2023. Data from Dubbo, a rural base hospital with a physician-led model for renal access, was compared to other NSW Hospitals coded as either rural or urban. Statistical analysis was conducted using Pearson's chi-square test to assess the significance of differences in patient outcomes, with a p-value of less than 0.005 considered significant. Results: The analysis demonstrated that the physician-led rural dialysis access clinic at Dubbo achieved significantly higher rates of permanent vascular access at first haemodialysis compared to combined rural and urban centres in NSW. Dubbo reported a rise in permanent access from 40%-75% between 2020 and 2023 (chi-square 20.851 (p = 0.002)). In contrast, rural centres averaged 46% and urban centres 41% for permanent access. Conclusion: The findings suggest that rural physician-led renal clinics may contribute to improved patient outcomes in haemodialysis, particularly regarding increasing the use of permanent vascular access. Further research is needed to confirm these results across a broader range of physician-led clinics and to account for potential confounding factors. Future studies should consider retrospective cohort analyses to explore the long-term benefits of this approach.

11:14 am

[Establishing Dialysis Access in Parallel: Single-Centre Outcomes of Concurrent PD Catheter and AV Fistula Procedures](#)
[Yu Shan Neo](#)

11:20 am

[Discussion](#)

11:30 am

[Environment & Surgery](#)

11:38 am

[Strategies to increase environmental sustainability and reduce waste relevant to endovascular surgery - A Scoping Review](#)
[Aaron Huang](#)

Aim: This scoping review aims to identify, categorise, and evaluate current strategies for increasing environmental sustainability in endovascular theatres, assessing their effectiveness for sites seeking to implement them. **Background:** Combining the output of healthcare worldwide would rank as the 5th-largest greenhouse gas-producing nation, with a significant contribution from operating theatres. Endovascular and hybrid procedures are resource-intensive environments that generate substantial medical waste, with waste disposal contributing significantly to healthcare's carbon footprint. Multiple strategies have been described as relevant to endovascular theatres, spanning vascular surgery, interventional radiology, cardiology, and neurology. **Method:** Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) framework, a comprehensive search of Medline, Embase and Cochrane Library was carried out. Studies included in the review were selected by two authors (AH and SL) after a blinded review based on their relevance to waste reduction and environmental sustainability in endovascular surgery. **Results:** Current findings highlight differing themes for interventions to reduce environmental impact, including optimising waste segregation to increase the recycling of uncontaminated medical waste, educating staff to improve decision-making regarding resource utilisation and waste disposal, and enacting hospital-level policies that promote sustainability. **Conclusion:** Sustainability initiatives in endovascular surgery require a multifaceted approach. This review will explore themes in the literature relevant to endovascular surgery, including current interventions to increase sustainability and reduce waste, and assess their environmental and clinical impact.

11:44 am

[Small Particles, Big Problems: A Scoping Review of Microplastics in Vascular Surgery](#)
[Lucille Vance](#)

Purpose: Microplastics and nanoplastics (MNPs) are increasingly present in the global environment as production of plastics increases despite our understanding of their impact on health remaining limited. This review serves to understand the extent and type of evidence in relation to the role of MNPs relevant to the field of vascular and endovascular surgery. **Methodology:** Using the PRISMA-ScR guidelines, a search of MEDLINE, Embase and Cochrane Library databases was undertaken from inception to until 24 March 2026. Eligibility criteria included studies published in English, contained human population groups, and examined MNPs in a context relevant to vascular and endovascular surgery. Studies were screened during a blinded review by two authors (LV, AH). **Results:** 2234 articles were identified from database searches with 28 articles meeting eligibility criteria for review. Most articles identified were reviews and thematically reported on the role of MNPs in cardiovascular risk factors via increased rates of atherosclerosis, thrombosis and reduction in vascular bed integrity. Outcomes-based studies reported higher concentrations of MNPs within vascular and renal tissue correlating with increased severity and complications of cardiovascular disease, including stroke and myocardial infarction, and chronic renal disease. Observational studies identified iatrogenic MNPs associated with therapeutics including percutaneous and endovascular devices, continuous renal replacement therapy and haemodialysis circuits, and extracorporeal membrane oxygenation circuits. **Conclusion:** The effects of MNPs within the cardiovascular system identifies roles in cardiotoxicity, thrombosis, inflammation and immunomodulation. As such the field of vascular and endovascular surgery is likely to see an increase in disease presentation and severity with effects on management and surgical outcomes not yet revealed.

11:50 am

[Discussion](#)

Scientific Session - [Vascular Nursing](#)

Focus: Patient perspective, co-morbidities, MDT

11 September 2026

12:30 pm - 1:30 pm
Lunch

Catering - [Vascular Surgery](#), [Vascular Nursing](#)

11 September 2026

12:45 pm - 1:15 pm
Gore Lunchtime Symposium

Scientific Session - [Vascular Surgery](#)

11 September 2026

1:30 pm - 3:00 pm
Abdominal Aortic Aneurysm & Training Future Aortic Surgeons

Scientific Session - [Vascular Surgery](#)

1:30 pm

[The role of women in changing the landscape of Australian Vascular Surgery: Advancements, Challenges and future directions](#)

[Pooja Krishnaswamy](#)

Objectives: The proportion of female doctors in surgery is underrepresented when compared to other medical specialties. The Royal Australian College for Surgeons (RACS) and the Australian and New Zealand Society of Vascular Surgery (ANZSVS) have increased awareness in the importance of gender diversity to create an equitable surgical workforce that reflects community. This study explored the current state of women in Vascular Surgery in Australia and New Zealand, including contributions to Vascular Surgery research. Methods: Demographic data was extracted from the ANZSVS Member 2024 database and Health Workforce Data Australia 2024. A PubMed search of each vascular surgeons publications from years 2018 to 2024 was performed by two independent reviewers. Data collected included date of publication, type of study and level of research evidence. Results: Despite 54% women represented in the current medical workforce, only 17% of the current vascular workforce are women. In 2024, 22% of vascular surgical trainees were female. Over 5 years, the proportion of female trainees has slowly increased. During the 2025 Vascular SET intake, there was a significant increase in accepted female applicants of 64%. Compared to other surgical subspecialties general surgery continues to lead in gender diversity. Women vascular surgeons contribute to vascular surgical publications equally to their male counterparts where two of the the top ten publishing vascular surgeons were women. Conclusion: Gender diversity in Vascular Surgery is vital to ensure equitable representation of the community. This study sheds insight into the representation of women in vascular surgery and their contributions to research.

1:38 pm

[Open AAA Training: National Decline, Local Success](#)
[Adam Beck](#)

1:46 pm

[Patient-Specific Aortic Simulation for Training and Procedural Planning](#)
[Lucy Guazzo](#)

1:52 pm

[Open aortic surgery in Australia over 25 years: an analysis of the trends and its impacts on vascular surgery trainees.](#)
[Shawn Ng](#)

Purpose In Australia, peripheral artery disease affects over 20% of the population aged 75 and over, and the prevalence of abdominal aortic aneurysm has remained at 4-6% over the last 20 years. Despite this prevalence of occlusive and aneurysmal disease, rates of open aortic surgery have been decreasing. This could be driven by risk factor modification such as smoking cessation, greater control of hypertension and hypercholesterolaemia, and a shift towards an endovascular-preferred approach. This study investigates this decreasing trend and its direct impact on vascular surgery trainees. **Methodology** Medicare Benefits Schedule item numbers for open and endovascular interventions for occlusive and aneurysmal disease were identified. Aggregated data was obtained from the Services Australia Medicare website between 2000 and 2025. Results were tested for statistical significance, and trainee data was extracted from the Australian and New Zealand Society for Vascular Surgery. **Results** Total abdominal aortic open operations across Australia decreased from 152 in 2000 to 45 in 2025 ($p < 0.0001$). Negative binomial regression identified an average yearly decline of 4%. Endovascular aneurysm repairs and aortoiliac stents showed a statistically significant increase over 25 years. These findings were corroborated by data within the Australasian Vascular Audit (AVA). With 45 open operations and 52 trainees in 2025, this represents 0.86 cases per trainee per year. This limited case number, compounded by an uneven distribution of cases among hospitals, results in minimal exposure for trainees and has potential implications for trainee proficiency in open aortic surgery. **Conclusion** This study highlights the significant decrease in open abdominal aortic operations across Australia and its impact on vascular surgery trainees. Further research into this can contribute to a better understanding of these challenges and guide future improvements to vascular surgery training.

1:58 pm

[Panel Discussion/Debate: Open Aortic Surgery is a Dying Art and Should be Centralised](#)

2:12 pm

[A contemporary analysis of small abdominal aortic aneurysm growth patterns](#)
[Nishanth Wood](#)

Purpose: The growth patterns of small abdominal aortic aneurysms (AAA) have been the subject of several randomised trials and summarised by level 1 analyses. However, there has been a change in the epidemiology of the AAA population, specifically a reduction in smoking rates, older age at presentation, and better cardiovascular risk management, which might affect AAA growth (1). Furthermore, AAA growth data in the Māori population has not been previously reported. The hypothesis of this study was that the background epidemiological changes and improvements in medical management slow the growth of small AAA. **Methods:** Retrospective analysis of all patients with a small AAA who were undergoing longitudinal ultrasound surveillance in a tertiary vascular centre. The data were sourced from the Waikato Hospital Vascular Surgery database. There were 5153 scans included, with an average of 4.8 scans per person. **Results:** 1071 patients were enrolled in the small AAA ultrasound surveillance program, of whom 801 had >1 scan and were included in the analysis. 207 patients underwent AAA repair, and 358 patients died without repair. The median (range) age at the time of the first scan was 74 (45-97). The overall mean growth rate was 2.15mm/year and the median growth rate was 1.7mm/year. There were 224 (28%) women and 83 patients identified as NZ Māori. The median growth rate for men was 1.76mm/year and for women 2.28mm/year. The median growth for Māori men was 1.82mm/year and for Māori women 2.63mm/year. **Conclusions:** Growth of AAA in contemporary patients appears slower than that reported previously. Growth rates in women were higher, with the fastest growth occurring amongst Māori women, which requires further attention to reduce this disparity. **References:** 1. Prendes CF, Gouveia e Melo R, Caldeira D, D'Oria M, Tsilimparis N, Koelemay M, et al. Systematic Review and Meta-Analysis of Contemporary Abdominal Aortic Aneurysm Growth Rates. Eur J Vasc Endovasc Surg. 2024;67(1):132-45.

2:20 pm

[Relative Intraluminal Thrombus Burden Predicts Aneurysm Volumetric Progression: A Longitudinal Analysis](#)
[Chinmay Sharma](#)

2:26 pm

[The Invisible Threat: Quantifying Missed Opportunities to Diagnose AAA](#)

[Anantha Narayanan](#)

2:32 pm

[Crossed-Limb Endovascular Aneurysm Repair: Mid-Term Outcomes from a Multicentre Western Australian Cohort](#)

[Tishanthan Pathmarajah](#)

Purpose: Crossed-limb deployment during endovascular aneurysm repair (EVAR) is occasionally required in patients with challenging anatomy to facilitate contralateral gate cannulation. Concerns regarding long-term durability have limited widespread adoption. This study compared graft-related outcomes following crossed-limb and conventional EVAR deployment. Methods: A retrospective multicentre review was performed of all patients undergoing infrarenal EVAR with the Gore Excluder endograft across seven Western Australian hospitals between 2013 and 2018. Patients treated with crossed-limb EVAR were compared with conventional deployment. Primary outcomes included graft limb occlusion, endoleak and reintervention. Secondary outcomes included perioperative and mid-term mortality, with three-year follow-up. Results: A total of 215 patients were analysed, including 83 crossed-limb and 132 conventional EVARs. Mean age was 70.5 years and 86% were male. No graft limb occlusions occurred in the crossed-limb cohort, while three occurred following conventional EVAR (0% vs 2.3%, $p=0.267$). Type I endoleak occurred in one patient in the crossed-limb group and two patients in the conventional group (1% vs 1.5%, $p=0.85$). No Type III endoleaks occurred in the crossed-limb cohort, whereas two occurred in the conventional group (0% vs 1.5%, $p=0.524$). No 30-day mortality occurred in the crossed-limb cohort, compared with one death in the conventional group (0% vs 0.7%, $p=0.427$). No aneurysm-related mortality occurred in either group at three years. Late non-aneurysm-related mortality was comparable between groups (1% vs 3%, $p=0.387$). Conclusion: Crossed-limb EVAR demonstrated durable outcomes comparable to conventional deployment, with no increase in graft limb occlusion, endoleak, reintervention or mortality through mid-term follow-up. These findings support crossed-limb deployment as a safe and effective strategy in patients with challenging aortoiliac anatomy undergoing EVAR.

2:38 pm

[Impact of a Hospital-Wide "Code AAA" Protocol on the Management of Ruptured Abdominal Aortic Aneurysm: A Retrospective Cohort Study](#)

[Zaynab Alghurairy](#)

Purpose Ruptured abdominal aortic aneurysm (rAAA) is a time-critical emergency with reported mortality of 30-50%. In June 2019, Northern Health introduced a hospital-wide "Code AAA" protocol to expedite activation, CT imaging, resuscitation and transfer to theatre. We evaluated its impact on process metrics, perioperative morbidity and mortality. Methods Single-centre retrospective cohort study of consecutive patients undergoing emergent repair of rAAA following emergency department presentation. Included patients were stratified by presentation before (Jan 2010 - Jun 2019; $n=27$) or after (Jun 2019 - May 2026; $n=16$) protocol implementation. Baseline characteristics, process and operative metrics, and outcome data were extracted and comparative analyses were performed. Results Baseline characteristics were comparable, though the post cohort was older (pre-protocol median age 75 years, post 82.5 years). EVAR use rose markedly (15% pre vs. 75% post, $p<0.001$). Median triage-to-theatre time trended shorter (251 minutes pre vs. 179 minutes post, $p=0.16$), and 30-day mortality was similar across the cohorts (pre 41%; $n=11/27$ vs. post 44%; $n=7/16$, $p=1.0$). The post-protocol cohort received significantly less blood product, both intraoperatively (pre-protocol median 4 units vs. post 2 units, $p=0.022$) and in total (7 pre vs. 4 post, $p=0.029$). Following the implementation of the protocol, median inpatient stay was lower at 6 days, compared with 8 days prior to implementation ($p=0.25$). Conclusion: Following implementation of the Code AAA protocol, we observed a non-significant trend towards expedited operating theatre transfer, reduced blood product use and shorter inpatient stay in the emergent management of ruptured AAA. While a shift toward endovascular repair was noted over the same period, this was observational. These findings support the value of coordinated, protocolised pathways for time-critical vascular emergencies and warrant confirmation in larger, multi-centre cohorts.

2:44 pm

[A 12-Year Experience With Aortic Graft and Endograft Infection; The Importance of Identifying a Causative Organism](#)

[William Ju](#)

2:50 pm

[Discussion](#)

Scientific Session - [Vascular Nursing](#)

Emerging treatments, wounds, goals of care & palliation

11 September 2026

3:00 pm - 3:30 pm
Afternoon Tea

Catering - [Vascular Nursing](#), [Vascular Surgery](#)

11 September 2026

3:30 pm - 4:30 pm
Summit Showdown

Scientific Session - [Vascular Nursing](#)

Expert panel debates: rare, complicated, challenging or novel cases

3:30 pm - 5:30 pm
Trauma, Vascular Foundation & Surgical Training in 2026

Scientific Session - [Vascular Surgery](#)

3:30 pm

[Sharp impact: Penetrating Thoracic Trauma at the Northern Territory's Major Trauma Centre \(NT MTC\) 2020–2025](#)

[Fergus Walsh](#)

Purpose Penetrating thoracic trauma is a major cause of morbidity and mortality in the Northern Territory (NT), where remote geography creates trauma system challenges. This study describes epidemiology, injury patterns, management, outcomes, and vascular injury burden of penetrating thoracic trauma at the NT Major Trauma Centre (NT MTC). Methodology A retrospective cohort study used the Trauma Registry. Adults admitted with penetrating thoracic trauma between 1 January 2020 and 31 December 2025 were included. Demographics, injury patterns, thoracic AIS severity, management, vascular injuries, and outcomes were analysed descriptively. Results 201 patients included; superficial breast injuries excluded. Median age was 33 years; 141 (70%) were male and 170 (85%) Aboriginal and Torres Strait Islander. Assault accounted for 177 (88%), with 148 (74%) presenting after hours. Median ISS was 5, and 38 (19%) sustained major trauma (ISS >13). Thoracic injury severity was minor in 75 (37%), moderate in 47 (23%), serious in 59 (30%), severe in 10 (5%), and critical in 10 (5%). Common injuries were pneumothorax (65), haemopneumothorax (36), lung laceration/contusion (28), and haemothorax (15). Major thoracic vascular injury occurred in seven patients, including six arterial injuries. Although uncommon, these were associated with severe injury patterns and rapid deterioration. Cardiac injury occurred in six patients, all critical. Overall in-hospital mortality was 2.5% (5/201), rising to 20% in critical injuries. Conclusion Penetrating thoracic trauma at NT MTC predominantly affects young Aboriginal and Torres Strait Islander men and is overwhelmingly assault-related. While most injuries are minor to moderate, a small but important subgroup sustains major vascular and cardiac injuries associated with significant morbidity and mortality. This data provides a contemporary benchmark for penetrating thoracic trauma in the NT and support development of dedicated thoracic trauma pathways.

3:38 pm

[Vascular access escalation in major trauma: does circulation need a structured algorithm?](#)

[Davina Daudu](#)

Background: Rapid vascular access is essential for haemorrhage resuscitation in major trauma. Pathways for inadequate vascular access are less defined. We investigated access escalation, triggers and mortality in severely injured trauma patients. Methods: Patients were identified from the Royal Perth Hospital trauma registry, and a retrospective review was performed of those requiring vascular access during prehospital or ED resuscitation from January-December 2024. Variables included demographics, injury severity score (ISS), cardiac arrest, access type, massive transfusion protocol (MTP) activation and mortality. IO/CVC escalation was defined as intraosseous access, central venous catheter, MAC line or large sheath. Escalation trigger was MTP activation and/or cardiac arrest. Fisher's exact and Mann-Whitney U tests were used. Results: Thirty-eight eligible patients were identified. Median age 45.5 years, 68.4% male, median ISS 26. Cardiac arrest occurred in 8/38 (21.1%), MTP was activated in 14/37 (37.8%), in-hospital mortality was 10/38 (26.3%) and 24-hour mortality was 8/38 (21.1%). Prehospital PIVC was documented or attempted in 32/38 (84.2%), prehospital IO was used in 2/38 (5.3%). In ED, PIVC was documented in 24/38 (63.2%), IO in 2/38 (5.3%), and CVC/MAC/large sheath in 7/38 (18.4%). IO/CVC escalation occurred in 9/38 (23.7%). All escalations occurred in patients with MTP activation and/or cardiac arrest (9/18 vs 0/20, $p < 0.001$), but only half of trigger-positive patients were escalated. Escalation was more common with MTP activation (6/14 vs 2/23, $p = 0.035$). All cardiac arrest patients died in hospital (8/8 vs 2/30, $p < 0.001$), while ISS did not differ by survival. Conclusion: Mortality clustered around physiological collapse rather than ISS, yet escalation beyond PIVC occurred in only half of patients with MTP activation and/or cardiac arrest. These findings support a structured circulation-access algorithm for major trauma.

3:46 pm

[Portal and Superior Mesenteric Venous Injury: Changing Resuscitation and Survival Over Two Decades](#)

[Ashton Arthur](#)

3:52 pm

[Three phenotypes of inferior vena cava and common iliac vein injuries at a Level 1 Trauma Centre: A ten-year retrospective study](#)

[Davina Daudu](#)

Purpose: Central abdominal venous trauma is rare and poorly standardised. We describe phenotypes, management and outcomes after inferior vena cava (IVC) and common iliac vein (CIV) injury at a Level 1 trauma centre. Methodology: IVC/CIV injuries from 2015-2024 were identified using ICD codes, trauma registry and theatre databases. Data included mechanism, associated injuries, physiology, Injury Severity Score (ISS), massive transfusion protocol (MTP), management, discharge antithrombotic strategy, complications and mortality. Fisher's exact and Mann-Whitney U tests explored group differences. Results: Twenty patients were included: 14 blunt and 6 penetrating/iatrogenic; median age 39 years; 15 male. Injuries involved IVC in 18 and CIV in 3. Twelve underwent intervention (11 open, 1 endovascular) and 8 were managed conservatively. Intervention patients had higher lactate than conservative patients (5.0 vs 2.35 mmol/L, $p = 0.01$); median ISS was 19 vs 26.5. Intervention patients were diagnosed intraoperatively in 11/12 with MTP activation in 11/12; all conservative patients were CT-diagnosed with no MTP activation ($p < 0.001$). Hollow viscus/mesenteric injury occurred in 7/12 intervention patients and 0/8 conservative patients ($p = 0.015$). In-hospital mortality was 4/6 after blunt intervention, 1/6 after penetrating/iatrogenic intervention and 0/8 after conservative management. Among 15 survivors, discharge strategy was none in 8, aspirin in 3 and therapeutic anticoagulation in 4. No venous thromboembolism (VTE) or venous injury-related complication was documented during median 44-month survivor follow-up. Conclusion: Blunt polytrauma requiring intervention carried high mortality, while CT-detected stable venous injury was managed non-operatively without VTE despite variable antithrombotic practice. Multicentre data, standardised reporting, surveillance imaging and antithrombotic pathways are needed.

3:58 pm

[War as a Catalyst for Vascular Innovation: From World Wars to Modern Hybrid Conflict](#)

[Paulina Bruessel](#)

Introduction: Armed conflict has driven major advances in vascular surgery, transforming uncontrolled haemorrhage from a fatal event into a survivable injury. From ligation and amputation in World War I to systematic repair strategies in the Vietnam War, conflict has shaped both techniques and systems of care. Registry and military data demonstrate substantial reductions in mortality and limb loss with the evolution of vascular repair, organised evacuation, and damage control principles. Methodology: This study synthesises historical and contemporary evidence from major conflicts. Insights are drawn from modern combat casualty datasets, including reports from the Russo-Ukrainian War, alongside key studies on temporary intravascular shunting, damage control surgery, and haemostatic resuscitation. Vascular and trauma literature informs analysis of changing injury patterns and treatment strategies. Results: Modern

warfare involves high-energy blast and fragmentation injuries causing complex, multi-level vascular trauma with severe soft tissue damage. Survival has improved with early haemorrhage control, forward surgical teams, and flexible evacuation systems. The use of whole blood transfusion, “walking blood banks,” and temporary vascular shunts is associated with improved limb salvage and reduced mortality. Emerging technologies such as bioengineered grafts and infection-resistant conduits show promise, though long-term outcomes remain under evaluation. Conclusion: The relationship between war and vascular innovation is cyclical. Advances in haemorrhage control, resuscitation, and reconstruction improve survival but respond to increasingly destructive injuries. As modern conflicts strain evacuation systems and increase mass casualties, there is a need for portable, resilient, and integrated vascular care. Addressing these challenges requires both technical progress and reflection on the human cost driving innovation.

4:06 pm

[Long-term TEVAR Aortic Remodelling in Blunt Traumatic Aortic Injury Patients](#)

[Omar Ayoub](#)

Purpose Thoracic Endovascular Aortic Repair (TEVAR) is the preferred treatment for blunt traumatic aortic injury (BTAI) due to lower morbidity and mortality than open repair. However, long-term outcomes, particularly in the predominantly young BTAI population, remain poorly understood. Ongoing aortic growth and remodelling may affect stent durability and contribute to late complications. This study evaluated long-term aortic remodelling and stent durability following TEVAR for BTAI. Methodology Patients with acute BTAI treated with TEVAR at Waikato Vascular Surgery Department between 2009 and 2026 were retrospectively reviewed. Computed tomography angiography (CTA) was analysed pre-operatively, immediately post-operatively, and at early (1–2 years), mid-term (3–7 years), and late (8–13 years) follow-up. Aortic diameters were measured at the mid-ascending aorta, pre-lesion/stent, peri-lesion/stented, post-lesion/stent, and celiac artery levels. TEVAR-related complications and reinterventions were recorded. Patients without baseline CTA and 30-day deaths were excluded. Results Thirty-five patients were included, with a median age (range) of 31 years (17–78); 80% were male. Four patients (11%) were lost to follow-up. Median follow-up (range) was 31.8 months (1.3–176.2). Grade III injuries accounted for 77% of cases. Aortic diameters increased over time at all sites, with no significant differences in growth between regions ($P>0.05$). The stented segment demonstrated less diameter increase than non-stented regions. Three TEVAR-related complications required reintervention at 1, 3, and 6 years; all were successfully managed. Conclusions TEVAR demonstrated durable long-term performance and favourable aortic remodelling following BTAI. Similar growth between the healthy and injured segments supports the biomechanical compatibility of TEVAR. Although limited by sample size, these findings suggest reduced surveillance intensity may be feasible in selected patients and warrant investigation in larger studies.

4:12 pm

[SUNDAY trial insights: clinical perspective on medical therapy in uncomplicated type B aortic dissections](#)

[Erin Saricilar](#)

Background: Medical therapy is the cornerstone of managing uncomplicated type B aortic dissections (uTBAD), however there are limited guidelines on its implementation. This study aimed to investigate variations in the interpretation and implementation of medical therapy among principal investigators of an ongoing international randomised clinical trial on uTBAD management. Methods: A cross-sectional questionnaire-based study was conducted among all principal investigators participating in the Scandinavian trial of Uncomplicated Aortic Dissection Therapy (SUNDAY) trial across 7 countries. A secure online survey was distributed and entered into REDCap, collecting categorical data on different aspects of medical therapy, including therapy targets, reporting standards, medical management and investigations. Results: A total of 34 of 46 investigators responded (74%). While 31 (91%) agreed upon blood pressure targets of less than 120mmHg, refractory hypertension was defined as blood pressure exceeding 140mmHg by 12 (35%), with 17 (50%) considering the number of antihypertensives used to determine refractory hypertension of which 8 (24%) set this at >3 , and 9 (27%) at >5 . The upper limit for heart rate was agreed as 60 bpm by 20 (59%). There was no agreement on the definition of refractory pain, with 7 (21%) not even considering it in decision-making. There was notable variation in reporting standards regarding chronicity, with 11 (32%) deeming hyperacute to be <24 hrs, 13 (38%) deeming it <48 hrs and 5 (15%) not considering it at all. 29 (85%) stated that they have a standardised hospital protocol for medical therapy for acute uTBAD. There was general agreement on escalation of anti-hypertensives in acute uTBAD with 30 (88%) starting with IV labetalol as first line, followed by calcium channel antagonists by 13 (38%) as second- and third-line treatments. Adjunctive medications were used consistently with 20 (59%) commenced statins as part of medical therapy and 22 (65%) commenced life-long single antiplatelets.

4:16 pm

[Panel Discussion/Debate: What is the role for a clamshell now in the endovascular era? Who should do REBOA?](#)

4:31 pm

[Duplex Ultrasound Surveillance after Endovascular Therapy for Peripheral Arterial Disease: Study Protocol for the SURVEIL Randomised Controlled Trial](#)

[Thomas Warburton](#)

Purpose: Duplex ultrasound (DUS) surveillance following femoropopliteal endovascular therapy (EVT) is widely practised to detect restenosis and guide pre-emptive reintervention. An ANZSVS survey confirmed 83% of vascular surgeons perform routine post-EVT DUS surveillance, yet this resource-intensive practice lacks adequately powered randomised evidence. SURVEIL aims to determine whether routine DUS surveillance reduces target vessel occlusion, major adverse limb events (MALE), and death compared to clinical surveillance alone. Methodology: SURVEIL is a multicentre, open-label, superiority randomised controlled trial across vascular surgery units in Australia and New Zealand (HREC: 2025/ETH01129; ACTRN12625000889459). Adults with a patent femoropopliteal target vessel at 4–6 weeks post-EVT for symptomatic PAD are randomised 2:1 to DUS plus clinical surveillance versus clinical surveillance alone. Both arms undergo clinical assessment and ankle-brachial pressure index measurement at 3, 6, 9, 12, 18, and 24 months. The primary endpoint is freedom from a composite of target vessel occlusion, MALE, or death at 24 months, analysed by Kaplan–Meier methods and log-rank test (intention-to-treat). Secondary endpoints include target lesion revascularisation, patency, symptomatic improvement, quality of life, and cost-effectiveness. A sample size of 288 achieves 90% power to detect a 20 percentage-point difference, with an adaptive interim analysis permitting up to 50% sample size increase. Results: Recruitment commenced in 2026. Results are anticipated following 24-month follow-up of all enrolled participants. Conclusion: SURVEIL is the first pre-registered, adequately powered, multicentre RCT evaluating DUS surveillance following femoropopliteal EVT for the full clinical spectrum of symptomatic PAD. Results will directly inform international clinical guidelines and healthcare resource allocation.

4:35 pm

[Building the Global Vascular Workforce Through Collaboration](#)

[Palma Shaw](#)

4:45 pm

[Vascular Surgery Training: The New Program](#)

[Sarah Aitken](#)

4:55 pm

[Vascular Surgery Training: Selection in 2027](#)

5:05 pm

[Challenges of Training in 2026: Panel Discussion](#)

11 September 2026

4:30 pm - 5:30 pm
ANZSVN AGM

Business Meeting - [Vascular Nursing](#)

11 September 2026

7:30 pm - 10:30 pm
Conference Dinner

Speciality Dinner - [Vascular Surgery](#), [Vascular Nursing](#)

12 September 2026

7:00 am - 10:00 am
Wellness Morning - SALVAGE Fun Run

Breakfast Session - [Vascular Nursing](#), [Vascular Surgery](#)

From arteries to asphalt—gather your colleagues, family and friends for a healthy dose of cardio as we come together for the SAL-VAGE Fun Run/Walk. The fun run has been organised as an initiative by a group of ANZSVS members (SAL-VAGE). SAL-VAGE aims to advance the prevention, diagnosis, and treatment of chronic limb-threatening ischemia (CLTI). All profits raised will go towards supporting the Vascular Foundation. Tickets can be purchased at the time of registration. If you wish to add a Fun Run ticket to your registration, please email vascular@surgeons.org.

7:00 am
[Discussion](#)

12 September 2026

10:00 am - 10:30 am
Morning Tea

Catering - [Vascular Surgery](#), [Vascular Nursing](#)

12 September 2026

10:30 am - 12:30 pm
Big Data & New Technology

Scientific Session - [Vascular Surgery](#)

10:30 am
[The Impact of Registry Participation on Vascular Surgical Quality](#)
[Adam Beck](#)

10:38 am
[AVA 2.0: An Update](#)
[Mark Jackson](#)

10:46 am
[Sex, size, and survival: rethinking aortic disease in women](#)
[Carlota Fernandez Prendes](#)

10:54 am
[Contemporary trends in treatment strategies for superficial venous incompetence: A VASCUNET Report from 2016-2022](#)
[Oliver Bernau](#)

Introduction: Chronic venous disease is a common condition and has a major impact on patients and health resources. The management of superficial venous incompetence has been subjected to level 1 evidence. The aim of this study was to report the contemporary management of superficial venous incompetence within the VASCUNET network. Methods: Vascunet registries were contacted and those that capture data on superficial venous disease were invited to participate. Patients treated with open surgery or endovenous therapy (radiofrequency/laser) between 2016-2022 were included and the data was harmonised. Eight

countries (Australia, New Zealand, Finland, Germany, France, Malta, Sweden, Switzerland) contributed to the dataset. The outcomes of interest included variation in treatment options over time, proportion of CEAP 6 and anaesthesia use. Results: 127,047 patients were included and the mean (standard deviation) age was 54.9 (14.6) and 65.8% were females. The proportion of endovenous therapy (compared to open surgery) ranged from 18-100% of cases. The most common endovenous therapy use was radiofrequency, followed by laser then glue. The great saphenous vein was the most common location of surgery/intervention, with proportions ranging between 60% and 80% for all countries. The proportion of general anaesthetic use reported ranged from 9.9% to 84.3%. Of those patients with CEAP 6 New Zealand had the highest reported group with 12.6% compared to France with 0.8%. There was an overall decline in open surgery with most of the change seen in Australia. There were no changes in the reported procedures performed during the pandemic (2020-2021). Conclusion: There are major variations in the management of patients with superficial venous disease across countries and such data might help and understand this variation and standardise patient care.

11:02 am

[Transatlantic management and outcomes of zone 2 TEVAR in type B aortic dissection](#)

[Erin Saricilar](#)

Background: Surgical management of type B aortic dissections (TBAD) remains significantly technically challenging to obtain an adequate proximal landing zone in the descending thoracic aorta. With increasingly more options to manage TBAD to seal in zone 2 with a thoracic endovascular aortic repair (TEVAR) the risk profile needs to be identified. Methods: Data was collected by centralised centres in Sweden, New Zealand, Hungary, USA, Serbia and Switzerland using a standardised database template. These were then passed through a turn-key R script that allowed for data federation without identifiable data leaving the local region. Analysis included patient characteristics, case mix analysis, peri-operative outcomes for acute and subacute/chronic TEVAR, predictors of outcomes with multivariate analysis for per-operative mortality and neurological events as well as a sensitivity analysis. Results: A total of 3666 (68%) men and 1720 (32%) women are included in the total analysis. There was a statistically significant decrease in zone 3 TEVAR from 2014 to 2025 ($p = 0.0083$). Acute TEVAR had a pooled mortality of 10.0%, while occluding the LSA for zone 2 TEVAR was 12.4% and zone 3 TEVAR alone was 11.6%. Acute TEVAR had an acute kidney injury rate of 19.6% with a stroke rate of 7.2%. However subacute/chronic TEVAR had an acute kidney injury rate of 6.9% and a stroke rate of 2.1%. Occlusion of the LSA in zone 2 TEVAR carried higher mortality in subacute/chronic (7.2%) and higher stroke rates in acute treatment (10.1%). Older patients had worse outcomes in open LSA zone 2 treatment and in pooled analysis, but no difference in zone 3 treatments. Conclusions: This is the largest dataset comparing zone 2 and zone 3 TEVAR using a first-of-its-kind turnkey R analysis for true data federation while protecting data residence. Acute TEVAR carries significant additional risks, while coverage and occlusion of the LSA does not increase stroke rates but has elevated mortality rates in TEVAR of any chronicity.

11:10 am

[Variation in abdominal aortic surgery outcomes in Aotearoa New Zealand: 'capacity to rescue' drives differences in mortality and 'days alive and out of hospital'](#)

[Anastasia Dean](#)

Introduction: Days Alive and Out of Hospital within 90 days of surgery (DAOH90) is a composite outcome that integrates death, hospital length-of-stay and hospital readmissions. The aim of this study is to investigate postoperative mortality, DAOH90, and 'failure to rescue' (FTR) following abdominal aortic (AAA) surgery across AoNZ. Methods: Population-based retrospective cohort study of all AAA interventions performed in AoNZ between 2010 and 2024, identified from National Minimum Dataset. Patients categorised using ACHI procedure codes: non-ruptured open repair, ruptured open repair, and endovascular repair. Outcomes included 90-day mortality, post-operative complications, FTR and DAOH90. National procedural coding data identified AAA intervention in public hospitals between January 2010 and December 2024. Results: 6,978 patients had aortic repair across nine hospitals, of whom 2,721 had open repair, 4,257 endovascular intervention. Overall 90-day mortality was 6.7% non-ruptured open repair, 35.7% ruptured open repair, and 3.9% endovascular intervention. There was marked inter-hospital variation in 90-day mortality in both intact open (OR 2.0, 1.3-3.0) and endovascular repair (OR 10.4, 2.6-42.2). Differences in post-operative complication rates were less pronounced in both intact open (OR 1.1; 0.9-1.3) and endovascular (OR 1.7; 1.3-2.2), however, this re-appeared when comparing post-operative mortality following a complication for both intact open (OR 2.1, 1.4-3.3) and endovascular intervention (OR 7.9, 1.9-32.6), suggesting hospital variation in mortality was primarily driven by differences in 'rescue' from complications (Spearman correlation coefficient = 0.82), rather than complication incidence (correlation coefficient = 0.45). Conclusion: Variation in outcomes after aortic surgery in AoNZ is driven by hospitals' capacity to rescue, rather than frequency of complications, suggesting the importance of postoperative monitoring and critical care access.

11:18 am

[Discussion](#)

11:26 am

[Moving the monitor: wireless Apple Vision Pro display of live angiography in the hybrid theatre](#)

[Daniel Thompson](#)

Purpose: During endovascular procedures, live imaging may not be equally visible to all members of the team. For assistants, trainees or operators at alternate access sites, visibility may be limited by room layout, C-arm position, equipment, monitor orientation or operator height. We used Apple Vision Pro as an augmented-reality headset to display live angiography as a movable spatial display without changing the standard monitor setup. Methodology: Multiple secondary imaging outputs from the hybrid theatre were routed through signal-normalisation and wireless video hardware to display live angiography on Apple Vision Pro. The headset was used as an additional display while standard theatre monitors remained primary. We describe the setup, practical use, advantages and limitations identified during bench and theatre testing. Basic feasibility data including case type, duration, technical issues and device battery use were collected. A video demonstration will be presented. Results: Live angiographic imaging was displayed wirelessly in the headset without a cable to the operator. The image could be moved and resized within the user's visual field while the standard theatre display remained unchanged. Technical issues were minimal, with signal compatibility and wireless network setup the main practical barriers during implementation. Battery life was identified as an important limitation for longer procedures. Conclusion: We describe a functional method for displaying live angiography on Apple Vision Pro using off-the-shelf hardware, as an adjunct to standard hybrid-theatre monitors. This approach will improve with dedicated software, full hybrid-lab input integration and partnership with imaging vendors. Further evaluation is required to determine reliability, practical value and integration into endovascular workflow.

11:32 am

[Computer-Assisted Arterial Thromboaspiration in Acute Limb Ischaemia and Beyond](#)

[Alan Rossman](#)

11:38 am

[Percutaneous VA-ECMO Decannulation: Faster Procedural Times and Fewer Groin Complications Compared with Surgical Cutdown](#)

[Dushan Miladinovic](#)

11:44 am

[Decoding the Dotted Line: Mitigating Medicolegal Risk and Socioeconomic Inequity in Vascular Consent via Next-Generation AI.](#)

[Mina Mikhael](#)

Purpose: Informed consent requires equitable health literacy. Standard vascular consent forms induce cognitive fatigue through excessive length and medical jargon, disenfranchising lower socioeconomic and culturally diverse patients. While artificial intelligence simplifies text, its ability to translate medicolegal risks without critical omission remains a literature gap. This study evaluates next-generation AI (ChatGPT-5.5) in democratising surgical consent, balancing accessibility with strict medicolegal safety. Methodology: Institutional consent texts for ten major vascular procedures (including EVAR and amputation) were sourced. Baseline word counts, jargon density, and readability (Flesch-Kincaid Grade Level [FKGL]) were calculated. Texts were processed by ChatGPT-5.5, prompted to enhance health literacy to an eighth-grade target. AI outputs were reassessed. Vascular clinicians graded AI outputs (1-5 scale) to ensure severe medicolegal risks (e.g., mortality, limb loss, stroke) were rigorously retained. Results: Baseline texts were highly inefficient (mean 1,678 words) and saturated with jargon, presenting a severe cognitive burden. ChatGPT-5.5 drastically improved accessibility, reducing the mean word count by 74% (to 435 words) and eliminating 88.8% of complex terminology. Readability was further optimised from a baseline FKGL of 5.75 to 5.10. Crucially, clinical grading confirmed 100% of severe medicolegal risks were safely preserved in the AI translation (Mean Clinical Safety Score 5.0/5). Conclusion: Verbose, jargon-heavy institutional consent protocols systemically disadvantage vulnerable populations, risking uninformed consent and medicolegal exposure. ChatGPT-5.5 provides a safe, highly efficient solution, reducing patient cognitive load by 74% while maintaining perfect medicolegal integrity. Clinicians in high-acuity environments can utilise this tool to generate accessible, patient-specific consent documents, fostering true shared decision-making.

11:50 am

[Discussion](#)

Scientific Session - [Vascular Nursing](#)

Wound debridement, cleansing, managing pain

12 September 2026

12:30 pm - 1:30 pm
Lunch

Catering - [Vascular Nursing](#), [Vascular Surgery](#)

12 September 2026

1:30 pm - 3:00 pm
Thoracic Aorta, Dissection & Spinal Cord Ischaemia

Scientific Session - [Vascular Surgery](#)

1:30 pm

[Global seasonal variation in prevalence and outcomes of acute aortic syndrome: A systematic review, meta-analysis, and comparison with a nationwide cohort study](#)
[Sameer Bhat](#)

1:36 pm

[Aortic dissection incidence, management and outcomes: a national population-based study](#)
[Erin Saricilar](#)

Background and Aims: Aortic dissection (AD) management requires early medical therapy and surgical intervention in applicable patients with type A aortic dissection (TAAD) or complicated type B dissection (TBAD). We aimed to assess incidence trends of AD in Sweden, and sex-based differences in management and outcome over 25 years. Methods: Swedish National Patient Register and Cause of Death Register were used to identify new AD between 1999 and 2023. Incidence, management and survival outcomes were analysed with relative survival comparing general population matching age, sex and year. Results: 15946 individuals had AD, 12225 admitted alive, and 6595 (53.9%) treated medically. Of 5630 surgically treated, 4141 (73.6%) represented TAAD; 1489 (26.4%) represented TBAD. Incidence increased significantly to 9.32/100,000, annual percentage change (APC) 1.4% (95%CI 1.2-1.6%). Incidence was lower for women (6.25/100,000) than men (10.52), but incidence increased threefold in women (APC 2.3% 95% CI 1.9-2.6%) than men (0.8% 95% CI 0.5-1.0%). Women presented older (mean 71.9 years; men 67.5 years, $p < 0.001$), had less surgical treatment (37.8% AD; 33.6% of surgical TAAD; 29.3% of surgical TBAD, $p < 0.001$) and poorer 10 year relative survival (medical: women 70.9%; men 84.1% $p = 0.0041$, surgical TAAD: women 86.6% men 94.9% $p < 0.0001$, surgical TBAD: women 70.9%; men 87.5% $p = 0.027$). Conclusion: This nationwide population-based study confirms increasing incidence of AD in Sweden, with persisting sex disparities in management, short- and long-term outcomes. These findings underscore needs for targeted interventions improving diagnosis, management and prognostication of AD, especially in women.

1:40 pm

[What's new in the 2026 ESVS Guidelines on Descending Thoracic and Thoraco-Abdominal Disease: Thoracic aorta, dissections and spinal cord ischaemia](#)
[Carlota Fernandez Prendes](#)

1:50 pm

[Building up from below: Endograft migration after TEVAR](#)

[Jun Cheul Park](#)

Objective: This study aimed to investigate the incidence, risk factors, and clinical significance of endograft migration (EM) following thoracic endovascular aortic repair (TEVAR). **Methods:** Consecutive patients undergoing TEVAR at a tertiary aortic referral centre between February 2004 and January 2025 were reviewed, with clinical and radiological follow-up until April 2026. Patients with at least 6 months of computed tomography angiography surveillance were included. EM was defined as endograft displacement ≥ 10 mm relative to fixed anatomical landmarks, or any displacement associated with symptoms or requiring treatment. Predictors of proximal endograft distal migration and distal endograft proximal migration were evaluated using univariable and multivariable logistic regression. Time to first EM was analysed using Kaplan–Meier methods. **Results:** Of 125 patients, 91 were male (72.8%), with mean age 59 years (range 15–87). The most common indications were type B aortic dissection ($n = 41$, 32.8%) and thoracic aortic aneurysm ($n = 41$, 32.8%). EM occurred in 33 patients (26.4%) over median follow-up of 73.7 months (IQR 37.0–109.0). Freedom from EM was 88.2% at 1 year, 75.2% at 3 years, and 68.4% at 5 years. Aortic elongation was associated with proximal endograft distal migration (OR 2.08, 95% CI 1.46–3.27; $p < .001$) and distal endograft proximal migration (OR 2.59, 95% CI 1.77–4.21; $p < .001$). Proximal-first deployment was independently associated with proximal endograft distal migration (OR 12.08, 95% CI 2.11–230.76; $p = .022$). Prompted by imaging surveillance, six patients with EM (18.2%) underwent EM-related reintervention; there was no EM-related mortality. **Conclusion:** EM after TEVAR was common on imaging surveillance, most occurring within the first two years. Aortic elongation was the most consistent anatomical predictor, while a proximal-first deployment in multi-device repairs was a strong, modifiable procedural risk factor.

1:56 pm

[Long term outcomes of optimal medical therapy in aortic dissection within the Swedish population](#)

[Erin Saricilar](#)

Background: While established clinical guidelines provide foundational recommendations for managing aortic dissection (AD), there is a significant lack of recent, large-scale evidence to definitively delineate optimal medical therapy, particularly concerning specific medication choices and dosages in the chronic period of the disease. **Methods:** Swedish National Patient Register and Cause of Death Register were used to identify new AD between 2006 and 2021. The impact of pre-dissection medications on survival was analysed. Landmark analysis of 10 year failure of medical therapy, aorta-related death and all-cause mortality was investigated with subgroup analysis of beta-blocker, antihypertensive and the role of adjunctive medications. All analyses controlled for age and sex. **Results:** A total of 12,223 patients were included, of which 4853 (39.7%) were females. Patients who were on metformin, an antiplatelet, statin or anticoagulant did not have a protective benefit to survival following AD, however metformin had a significant protective effect for 10 year failure of medical therapy ($p = 0.00622$). In patients with diagnosed diabetes, those on metformin also had a significant survival benefit ($p = 0.0362$). Non-selective beta-blockers had the poorest mortality compared to selective or alpha and beta-blockers ($p = 0.089$) though this wasn't significant for aortic death ($p = 0.52$) and a trend to more failure of medical therapy ($p = 0.072$). Being commenced on an anticoagulant and antiplatelet significantly increased all cause mortality while commencing a statin trended towards poorer all cause and aortic death. **Conclusions:** This is the largest analysed cohort focussing on optimal medical therapy for AD. The role of metformin having a protective aortic effects is demonstrated but requires more focussed investigation. Antihypertensive choice did not impact outcomes, though selective beta-blockers provide the best mortality and failure of medical therapy outcomes.

2:00 pm

[Early and late Vascular surgery interventions in patients undergoing acute Stanford type A aortic dissection repair: an 11-year single institutional experience](#)

[Michael Zhu](#)

Purpose: Data on the incidence, indications, and outcomes of Vascular interventions after acute Type A aortic dissection (ATAAD) repair are limited. **Methods:** We reviewed all patients undergoing ATAAD repair from 2015–2025 who subsequently needed vascular intervention. Interventions were classed as acute (≤ 14 days after index ATAAD repair), subacute (15–90 days), or late/chronic (> 90 days). Multidisciplinary consensus guided intervention decisions. **Results:** Among 128 ATAAD repairs, median age was 64.1 years, and 75.8% (97/128) were male. Index dissection extended beyond zone 2 in 62.5% (80/128). Median follow-up was 2.2 years (IQR 0.4–4.7). Overall, 24 patients (18.8%, 24/128) underwent vascular intervention: 12 acute, 3 subacute, and 9 late/chronic. 30-day mortality was 50% (6/12), 0% (0/3), and 0% (0/9). There were no late deaths. Acute indications were: lower limb ($N=3$), mesenteric ($N=3$), renal ($N=2$) or cerebral malperfusion ($N=2$), and symptomatic distal anastomotic new entry tear (DANE: $N=2$, treated with conformable thoracic stent graft (cTAG)). Subacute interventions were for symptomatic DANE ($N=3$, thoracic branched endoprosthesis (TBE)). Late/chronic interventions were for: progression of DANE and/or residual type B dissection ($N=6$; TBE ($N=3$), cTAG ($N=3$)), mesenteric ischaemia ($N=1$), aorto-iliac aneurysm ($N=1$) and leg claudication ($N=1$). Four patients underwent late cardiothoracic aortic reoperation for pseudoaneurysm. Cumulative incidence of vascular

and aortic interventions, with death as a competing risk, at 14days, 90days, 1, 3 and 5 years was 8.6%, 12.0%, 17.7%, 22.9%, and 29.9%. Conclusion: After ATAAD repair, vascular intervention was needed in almost 10% of patients acutely, and over 20% by 3 years. Acute interventions for refractory malperfusion carried high early mortality, whereas late interventions, principally for residual dissection progression, had no observed mortality. These findings support multidisciplinary decision-making, early malperfusion recognition and lifelong aortic surveillance.

2:06 pm

[A Kaupapa Māori qualitative study of young Aortic Dissection in Aotearoa New Zealand](#)
[Meg Beaumont](#)

2:12 pm

[Spinal cord ischaemia - an anaesthetist perspective](#)
[Helen Lindsay](#)

2:22 pm

[United States Aortic Research Consortium Insights on Spinal Cord Ischemia in Endovascular TAAA repair](#)
[Adam Beck](#)

1:30 pm - 3:00 pm

Workshop - Hands on, perfect your skills

Scientific Session - [Vascular Nursing](#)

ABPI, Negative Pressure, Compression bandaging

12 September 2026

3:00 pm - 3:30 pm

Afternoon Tea

Catering - [Vascular Nursing](#), [Vascular Surgery](#)

12 September 2026

3:30 pm - 5:30 pm

Trainee Presentations - Challenge the Experts

Scientific Session - [Vascular Surgery](#)

3:30 pm

[Multiple Visceral Aneurysms](#)
[Michael Zhu](#)

3:40 pm

[Complex Inferior Pancreatico-Duodenal Aneurysm with occluded coeliac artery](#)
[James Kellie](#)

3:50 pm

[Aneurysm Beyond the Aorta](#)
[Abhishekh Srinivas](#)

4:00 pm

[Atrian Appendage Occlusion Device in Distal Aorta](#)
[Lucas Hendy](#)

4:10 pm

[Pruning a tree of unwanted fruit](#)
[Hamish Tso](#)

4:20 pm

[High Pressure Situation](#)

12 September 2026

5:30 pm - 6:30 pm
ANZSVS Annual General Meeting

Scientific Session - [Vascular Surgery](#)

5:30 pm

[Discussion](#)

13 September 2026

8:30 am - 10:00 am
Complex Aortic: Arch, TAAA

Scientific Session - [Vascular Surgery](#)

8:30 am

[Real World Outcomes Compared with Trial Data for TAMBE: the USA Experience](#)
[Jason Lee](#)

8:40 am

[Real-World Outcomes of Thoracic Branch Endoprosthesis Repair for Aortic Arch Pathology: A Bi-Centre New Zealand Experience](#)
[Summer Hassan](#)

Introduction Thoracic branch endoprosthesis (TBE) is an endovascular alternative to hybrid and open arch reconstruction, allowing preservation of supra-aortic branch perfusion. We report the first bicentre New Zealand experience evaluating the safety and effectiveness of TBE across a broad spectrum of aortic arch pathology. Methods A retrospective review of all patients undergoing TBE at two tertiary New Zealand vascular centres from June 2023 to April 2026. Outcomes included technical success, perioperative mortality, neurological complications, branch patency, reintervention and survival. Results Forty-eight patients underwent TBE. Median age was 70 years (IQR 63–77), and 60% were male. Indications included thoracic aortic aneurysm (43%), aortic dissection (31%), penetrating aortic ulcer or intramural haematoma (22%), and traumatic aortic injury (4%). Thirty-five procedures (71%) were elective, 13 (27%) urgent, and one (2%) emergent. Zone 2 proximal sealing was utilised in 65% of procedures, while 35% required zones 0–1 repair. The left subclavian artery was the target branch vessel in 86% of cases. Median intensive care stay was 1 day (IQR 1–2), and median hospital length of stay was 5 days (IQR 3–6). Median clinical follow-up was 14.5 months (IQR 4.5–23.0). Technical success was achieved in all patients. Thirty-day mortality was 2.0%. Stroke occurred in 4.1% and spinal cord ischaemia in 2.0%. Despite the inclusion of complex arch pathology and urgent presentations, there was no retrograde type A dissection, device failure, or loss of target vessel patency observed during follow-up. Secondary interventions occurred in ten patients and were related to distal progression of underlying aortic pathology, endoleak management, or staged aortic repair rather than branch device failure. Conclusions TBE provides a safe and effective endovascular solution for a wide range of aortic arch pathologies in contemporary practice.

8:50 am

[Complex aortic management & outcomes: A perspective from Asia](#)

[Rajesh Dharmaraj](#)

9:00 am

[Early Clinical and Technical Outcomes of Inner-Branched Endografts in Complex Aortic Repair](#)

[Haywood Yeung](#)

9:06 am

[Discussion](#)

9:16 am

[Aortic arch and ascending aortic interventions: indications, evidence, and ethical considerations](#)

[Carlota Fernandez Prendes](#)

9:26 am

[Impact of multidisciplinary team meetings on management and outcomes for aortic disease: A scoping review of the literature](#)

[Sameer Bhat](#)

Purpose: Multidisciplinary team (MDT) meetings have enhanced shared decision-making in the oncology setting due to the complexity of available treatments. In view of the expanding endovascular and hybrid interventions, their evaluation in the vascular surgery setting is warranted.[1] This scoping review summarised the current evidence on MDT meetings in patients with any aortic disease. Methodology: The conduct of this study adhered to PRISMA methodology. Comprehensive systematic searches of the MEDLINE, EMBASE, Scopus, Web of Science, CINAHL and Google Scholar databases were independently performed by two investigators in December 2025. Studies implementing MDT meetings for consensus on management strategies among patients with any aortic disease were included. Data were synthesised thematically. Results: A total of 2,244 patients with aortic conditions were discussed at MDT meetings within six studies. All were retrospective cohort studies and reflected both contemporary and historic management practices (2010 until 2024). Aortic aneurysms were most frequently reviewed. MDT composition, meeting structure and processes were inconsistent and lacked standardisation. After MDT meetings were instituted, significant increases in aortic case volume and complexity were observed, together with reductions in time to definitive treatment and mortality. Conclusion: MDT meetings are emerging as a means of facilitating complex decision-making across a range of aortic conditions, and particularly among patients with aneurysmal disease. Despite the substantial variability in MDT frameworks, several improvements in clinical outcomes were recognised. Future efforts should aim to standardise MDT meeting processes and validate these systems-level changes through larger studies capturing a uniform set of outcomes. References: 1. Yates MT, Lopez-Marco A, Lee M, Adams B, Yap J, Uppal R, et al. Decision making of a specialist Aortovascular multidisciplinary team meeting. AME Surg J. 2022 Mar;5:2-2.

9:32 am

[Debate](#)

9:42 am

[Discussion](#)

13 September 2026

10:00 am - 10:30 am
Morning Tea

Catering - [Vascular Nursing](#), [Vascular Surgery](#)

13 September 2026

Scientific Session - [Vascular Surgery](#)

10:30 am

[The asymptomatic carotid stenosis patient: What have we learned from CREST 2](#)
[Wesley Moore](#)

10:40 am

[40 Years of Carotid Bifurcation Intervention: Is there a place for TCAR?](#)
[Bernard Bourke](#)

INTRODUCTION: Carotid bifurcation intervention (CBI) remains controversial and highly scrutinised (ref 1). The Crest 2 trial arguably helps guide treatment of asymptomatic high-grade stenotic disease. CBI in Australia and NZ has been CEA or TFCAS. The ENROUTE reverse-flow TCAR System introduced into Australia in March 2026 allows an additional method. METHODS: CEA commenced 20/2/86 evolving from GA / obligatory shunting through LA / selective shunting (LASS)/ vein patching through LASS / eversion CEA (LASSeCEA). TFCAS commenced 2/9/05 evolving to primary carotid stenting (PCS) avoiding a balloon. TCAR commenced 3/3/26 (choosing only high-grade asymptomatic stenoses). RESULTS: 2792 CBI (to 20/6/26). CEA: 2250; TFCAS: 531; TCAR: 11. LASSeCEA DWI rate of 3% is the lowest recorded and in the largest series published (ref 2). PCS: zero CVA/death (CD). TCAR: 10GA;1LA; zero CD. 5 TCAR stayed more than 1 night {2 persistent hypotension, 1 persistent bradycardia (BC), 1 random BC, 1 social reason}. CEA: 76% and TFCAS: 84% overnight, OPINIONS/CONCLUSIONS: TCAR is a safe, valuable addition for CBI. In our practice it will expand options, particularly for high carotid bifurcations. For high grade lesions stenting has a significantly increased rate of haemodynamic compromise compared to CEA.TCAR had a shallow learning curve for us. It will be steeper for those without stent experience but not as steep as TFCAS. It should be embraced by the ANZSVS to increase our “skin in the stent game”. In our practice CEA remains the gold standard for symptomatic patients but TCAR will challenge this with time. 1.Bourke BM. Intervention on the carotid bifurcation—75 years on, still not nailed. Editorial ANZ Journal of Surgery. 2025 Oct;95(10):1979 -1981 2.Bourke VC, Bourke BM, Beiles CB. Operative factors associated with the development of new brain lesions during awake carotid endarterectomy. European Journal of Vascular and Endovascular Surgery. 2016; 51:167–173.

10:48 am

[Optimizing Carotid Revascularization: Selecting Between CEA, TCAR, and TF-CAS](#)
[Nick Mouawad](#)

10:56 am

[A liberal carotid artery stenting strategy is safe in Australia](#)
[Enis Kocak](#)

Purpose/Aim Carotid artery stenting has historically been associated with a higher risk of perioperative stroke as compared to carotid endarterectomy (CEA), especially in the symptomatic population. After adopting a more liberal strategy to selecting patients for carotid artery stenting, we sought to evaluate the safety of this approach in Australia with modern techniques and technology. Methods We conducted a retrospective analysis of all patients undergoing transfemoral carotid artery stenting (tfCAS) and transcarotid artery revascularisation (TCAR) at our institution within the 36 months to September 2025. Patients were selected for tfCAS/TCAR where there was clinical equipoise between these and CEA, or a relative contraindication to CEA. The primary outcome was the 30-day ipsilateral stroke rate. All interventions were performed by two experienced operators. All patients were given dual antiplatelet therapy preoperatively and for at least 30 days postoperatively. Results 37 patients in total underwent carotid artery stenting procedures with a 100% technical success rate. 35 patients underwent tfCAS (95%) and 2 underwent TCAR with flow reversal (5%). Only 1 tfCAS patient did not have an embolic protection mechanism employed (due to severe distal tortuosity). 21 patients (57%) were symptomatic and 16 (43%) were asymptomatic. 23 lesions (62%) were high grade (80-99% stenosis). 18 patients (49%) received a dual-layer/micromesh stent. The ipsilateral stroke rate at 30 days and composite stroke/death rate at 30 days were both 0%. Conclusion A liberal carotid artery stenting strategy is safe in Australia with modern techniques and a reasonable case volume to maintain proficiency.

11:04 am

[Discussion](#)

11:14 am

[TCAR: Critical Steps Flatten the Learning Curve](#)

[Victor Bourke](#)

Background: Transcarotid artery revascularisation (TCAR) is a hybrid technique that reduces embolic risk by avoiding aortic arch manipulation and using direct carotid access with flow reversal cerebral protection. For the Vascular Surgeon it may offer a shorter learning curve than transfemoral carotid artery stenting (TF-CAS), with outcomes comparable to carotid endarterectomy (CEA) in selected patients. Methods: We report the introduction of a TCAR service within an Australian health service, focusing on proctoring, regulatory approval, and governance, contextualised by prior institutional outcomes with CEA and TF-CAS. Critical technical and pharmacological steps are outlined. Implementation aligned with Australian requirements for new interventional procedures. Author experience includes TF-CAS (n=270), TCAR (n=11; 5 primary operator), and CEA under local anaesthesia (n=173). Results: Eleven patients underwent TCAR (7 male), aged 62–91 years (mean 76). Comorbidities included ischaemic heart disease (n=7), diabetes (n=4), hypertension (n=7), and smoking (n=9). All lesions were asymptomatic high-grade stenoses (80–99%); 7 had St Mary's ratio >30. Technical success was 100%. All cases required pre-dilation; 5 required post-dilation. Ten stents were tapered and 40 mm in length. There were no perioperative strokes, deaths, or myocardial infarctions. Six patients were discharged the next day; five had delayed discharge due to hypotension (n=2), bradycardia (n=2), or social factors (n=1), requiring selective ICU and cardiology input. Conclusions: TCAR can be safely introduced by the Vascular Surgeon with appropriate proctoring, multidisciplinary planning, prior carotid experience, structured haemodynamic monitoring, and clear escalation pathways. Contemporary data support low stroke and mortality rates, and TCAR may play an increasing role in asymptomatic high-grade disease as trials such as CREST-2 further define revascularisation.

11:24 am

[Early TCAR experience with the ENROUTE System in Australia](#)

[Enis Kocak](#)

Purpose/Aim Transcarotid artery revascularisation (TCAR) is an established technique for carotid revascularisation in the USA, utilising a proprietary neuroprotection and stent system which, until recently, has not been available overseas. Select centres in Australia have adopted an “off-the-shelf approach” to establish flow reversal using existing non-proprietary equipment with satisfactory results. As one of the centres historically performing off-the-shelf TCAR, we sought to evaluate our TCAR results following the availability of the ENROUTE Neuroprotection and Stent Systems in Australia. Methods We conducted a retrospective analysis of all patients undergoing TCAR with the ENROUTE Neuroprotection and Stent Systems (Boston Scientific) at our institution from March to May 2026. Patients were selected for TCAR where they were considered high surgical risk under historical Centers for Medicare and Medicaid Services (CMS) carotid stent criteria, where they had risk factors making either CEA or TFCAS higher risk, or where there was clinical equipoise between techniques. The primary outcomes were the 30-day ipsilateral stroke rate and 30-day composite stroke/death rate. Results 10 patients in total underwent TCAR with the ENROUTE system during this period. 7 patients (70%) were symptomatic and 3 (30%) were asymptomatic. 5 lesions (50%) were high grade (80-99% stenosis). 7 patients received clopidogrel (70%) and 3 patients received ticagrelor (30%) as the P2Y12 inhibitor for their pre-operative and post-operative antiplatelet regimen. 3 patients (30%) were standard risk and 7 patients (70%) were high risk according to CMS carotid stent criteria. Technical success rate was 100%. The flow reversal time during the procedures was 10.8 minutes. The ipsilateral stroke rate at 30 days and composite stroke/death rate at 30 days were both 0%. Conclusion Our early experience with the ENROUTE Neuroprotection and Stent Systems suggests that it is a safe means of performing TCAR in Australia.

11:32 am

[Advancing TCAR: Contemporary Clinical Outcomes in the Era of Integrated Embolic Protection](#)

[Nick Mouawad](#)

11:40 am

[Intravascular Lithotripsy During Transcarotid Artery Revascularization: A Retrospective Analysis](#)

[Marisa Doran](#)

Purpose: Severe carotid artery calcification is a technical challenge during carotid revascularization and has been associated with suboptimal stent expansion and residual stenosis. Intravascular lithotripsy (IVL) has emerged as an adjunct for plaque modification; however, clinical experience in conjunction with transcarotid artery revascularization (TCAR) is limited. This study evaluated the safety and perioperative outcomes of IVL-assisted TCAR compared with TCAR alone. Methodology: A retrospective review was performed of patients undergoing TCAR at two affiliated hospitals between 2018 and 2024. Baseline demographics, comorbidities, procedural characteristics, and 30-day postoperative outcomes were analyzed. Patients undergoing IVL-assisted TCAR were compared with those undergoing standard TCAR.

Results: Among 723 patients undergoing TCAR, 19 (2.6%) underwent adjunctive IVL. Patients treated with IVL were older than those undergoing standard TCAR (median age 78 vs 73 years; $p=0.036$). Baseline comorbidities, symptom status, medication use, and degree of stenosis were similar between groups. IVL-assisted procedures required longer operative times (84 vs 70 minutes; $p=0.006$) but no increase in length of stay. No strokes, myocardial infarctions, deaths, cranial nerve injuries, reoperations, or other major perioperative complications occurred in the IVL cohort, compared with stroke, myocardial infarction, and mortality rates of 1.7%, 0.4%, and 0.1%, respectively, in the standard TCAR group. Conclusion: IVL during TCAR appears safe and feasible for the treatment of heavily calcified carotid lesions, achieving perioperative outcomes comparable to standard TCAR despite treatment of an older patient population. These findings support IVL as a useful strategy in selected patients with severe carotid calcification. Future studies incorporating CT imaging based calcium burden scoring and propensity-matched comparisons with carotid endarterectomy are underway.

11:48 am

[Prospective Study and Cost Analysis of Off-The-Shelf Transcarotid Artery Revascularisation - A Safe and Cost-Effective Solution?](#)

[Michael Na](#)

PURPOSE Transcervical Carotid Artery Revascularization (TCAR) combines the benefits of endovascular carotid stenting with cerebral protection through flow reversal, offering an alternative to conventional carotid endarterectomy (CEA) and to transfemoral carotid artery stenting (TF-CAS). Current TCAR protocols rely on a dedicated flow reversal device which carries considerable costs. This study aimed to demonstrate the feasibility and safety of TCAR performed with an off-the-shelf setup as an option for treatment of carotid disease. **METHODOLOGY** This prospective, open-label, multi-center study consecutively enrolled patients requiring carotid revascularization for internal carotid artery disease from July 2023 onwards. All procedures were performed under general anesthesia using an off-the-shelf flow reversal circuit comprising a standard 8 Fr sheath in the common carotid artery (CCA) and an 11 Fr sheath in the common femoral vein (CFV), connected by a wide-bore extension tube. No proprietary flow reversal or neuroprotection device was used. The primary endpoint was procedural success at 30 days (stent patent and without cerebrovascular accident, myocardial infarction, or death). **RESULTS** 26 patients were included, with a median age of 73 and 42% (11/26) having both anatomical and physiological high-risk factors. 73% (19/26) of the cohort had symptomatic disease. Median procedural time was 1h:21m, median flow reversal time 10m:48s. Procedural success was achieved in 96%. Material cost of the off-the-shelf setup (including stent) was 1,741 AUD, compared to 10,010 AUD for the dedicated flow-reversal device setup. **CONCLUSION** Off-the-shelf TCAR is technically feasible and appears safe, with 96% 30-days procedural success. The setup offers a dramatic cost reduction compared to dedicated flow-reversal device, and if confirmed in larger studies could offer a viable and cost-effective alternative to conventional CEA and TF-CAS.

11:54 am

[Declining Carotid Endarterectomy Volume with Preserved Safety and Guideline Adherence: A 15-Year Single-Centre Experience](#)

[Dushan Miladinovic](#)

12:00 pm

[Discussion](#)

13 September 2026

12:30 pm - 1:30 pm
Lunch

Catering - [Vascular Nursing](#), [Vascular Surgery](#)

13 September 2026

1:30 pm - 3:00 pm
The Final Word

1:30 pm

[When the Diagnosis doesn't fit: Looking beyond the obvious](#)

[Asha Malan](#)

1:42 pm

[Vascular Oncosurgery](#)

1:54 pm

[Developing an Oncovascular Service for Complex Retroperitoneal Tumours: A Twelve-Year Experience](#)

[Keely Gardiner](#)

Purpose: Retroperitoneal sarcomas (RPS) are rare, aggressive malignancies often requiring radical en bloc multivisceral resection. Major vascular involvement is a key determinant of resectability and may necessitate vascular reconstruction. This study describes patterns and outcomes of vascular reconstruction in RPS surgery at a high-volume sarcoma centre. Methodology: A retrospective review of primary RPS resections (2010–2022) was conducted at the State Sarcoma Service, Sir Charles Gairdner Hospital, Western Australia. Data included tumour type, vascular reconstruction, operative duration, length of stay, reoperation, readmission, mortality, and graft patency. Analyses included chi-squared testing and binary logistic regression. Results: A total of 129 patients underwent resection (mean age 58.6 years; 51% female). Vascular surgeons were involved in 76% of cases, and 30 patients (23%) required vascular reconstruction. Venous reconstruction was more common than arterial (20.2% vs 10.9%), most frequently associated with leiomyosarcoma and dedifferentiated liposarcoma, respectively. ECMO bypass was used in 22 cases (17.1%), exclusively for venous reconstruction. Inpatient and 1-year mortality were 2.3% and 9.3%, respectively. Increasing age was associated with higher 1-year mortality (OR 1.1 per year, $p=0.009$). Vascular reconstruction was associated with longer operative time (623 vs 360 minutes, $p<0.001$) and longer hospital stay (15 vs 12.5 days, $p=0.02$), but not with increased reoperation, readmission, or 1-year mortality. Conclusion: Vascular reconstruction is required in approximately one in five RPS resections and increases operative complexity and length of stay without adversely affecting short-term morbidity or 1-year mortality. These findings support the safety of aggressive oncovascular resection in a high-volume setting and highlight the role of multidisciplinary vascular involvement and adjuncts such as ECMO bypass in selected cases.

2:04 pm

[Global Vascular Surgery in Low and Middle Income Countries: An Analysis of Surgical NGO Representation](#)

[James Lockhart](#)

Objective: The 2015 Lancet Commission on Global Surgery highlighted a critical shortage of surgical care in low and middle-income countries (LMICs). Since then death and morbidity from surgical vascular disease in particular has grown in LMICs as life expectancy increases. Despite this, the role of surgical non-governmental organisations (s-NGOs) in addressing vascular surgical need in LMICs has not been characterised. Design: A cross-sectional survey of international s-NGOs operating in LMICs was conducted. Multiple search strategies were employed to engineer redundancy and increase sensitivity. Search strategies included literature review via PubMed and Google Scholar, a review of national charity registries, and searching independent NGO databases. NGOs were included if they demonstrated current activity and a commitment to delivering or expanding access to surgical care. Surgical specialties were identified and compared by frequency. Results: Of 1,242 organisation names identified, 398 unique s-NGOs met inclusion criteria. A plurality of s-NGOs provided multiple specialties ($n = 120$, 30.2%). The most common surgical specialties offered were ophthalmology ($n = 98$, 24.6%), paediatric surgery ($n = 84$, 21.1%) and plastic and reconstructive surgery ($n = 77$, 19.3%). The least commonly delivered specialty was vascular surgery ($n = 5$, 1.3%). Only two s-NGOs (the Global Vascular Companionship and the World Federation of Vascular Societies) were dedicated exclusively to vascular surgery. Conclusions: Vascular surgery remains critically underrepresented among international s-NGOs relative to other surgical specialties, despite a growing global burden of vascular disease in LMICs. Efforts to address this gap focus mainly on local capacity building and training rather than direct care provision as recommended by the Lancet Commission, though investment in global vascular surgery remains substantially lower than in other specialties.

2:12 pm

[A Qualitative Exploration of the Perceptions of Music Use by Healthcare Professionals in the Operating Theatre](#)

[Anantha Narayanan](#)

Background: In this abstract we present the final chapter on a thesis journey investigating the effect that

background music has on the operating surgeon. Studies from this thesis have been presented at ANZSVS conferences prior, including the BRAHMS study (an ANZSVS survey), the MOSART Study (field investigation) the STRAUSS Study (laboratory investigation). In this paper we use these previous studies to contextualise a final study where healthcare professionals' (HCPs) experiences of intra-operative music are explored qualitatively. Methods: Semi-structured interviews with seven HCPs (surgeons, anaesthetists, nurses) were analysed using qualitative content analysis with an abductive, critical realist approach. Results: Five themes emerged: (1) music reflects team cohesion; (2) contributes to therapeutic space; (3) is not a panacea; (4) enacts power and protection; and (5) serves as an environmental cue. Music fostered camaraderie and calm but could cause tension, reinforce hierarchy, and disproportionately affect some staff. Conclusions: Music plays a nuanced, multifaceted role in theatre. Team-led, flexible frameworks may best support inclusive, situationally appropriate use.

2:20 pm

[Left Common Carotid–Subclavian Transposition: A Native-Vessel Solution to Arch Debranching Before TEVAR](#)

[Abram Poznanski](#)

Purpose: Off-the-shelf and custom thoracic endovascular aortic repair (TEVAR) solutions for aortic arch and descending aortic pathologies have transformed contemporary treatment landscape. However, consideration must be given to arch and supra-aortic vessel anatomy to ensure both antegrade perfusion is maintained, as well as satisfactory proximal seal zones can be obtained. This study aims to compare left common carotid to left subclavian artery (LCCA-LSCA) transposition with conventional carotid–subclavian bypass/debranching for supra-aortic revascularisation in patients undergoing thoracic endovascular aortic repair (TEVAR). Methods and Materials: A single-centre case-control study was performed including consecutive patients undergoing TEVAR with supra-aortic reconstruction prior. Patients underwent either LCCA-LSCA transposition or conventional debranching with bypass. Primary outcomes included stroke, technical success, immediate LSCA patency, and 30-day mortality. Secondary outcomes included proximal landing zone length increase and reintervention rates. Results: 32 patients were included (Bypass/debranching n = 27; transposition n = 5). Technical success and immediate LSCA patency were achieved in 100% of cases in both groups, with no 30-day mortality. Stroke occurred in one patient (3.7%) in the bypass group and none in the transposition group. Reintervention was required in one bypass patient (3.7%) and none in the transposition cohort. Both techniques enabled equivalent proximal landing zone extension lengths to facilitate TEVAR. Conclusion: LCCA-LSCA transposition provides equivalent technical and anatomical outcomes to conventional bypass for LSCA revascularization and optimizing proximal landing zone length in TEVAR, while avoiding prosthetic graft use and additional anastomoses. It represents a safe and potentially more durable alternative in appropriately selected patients.

2:28 pm

[A contemporary evaluation of early and late aortic and non-aortic mortalities after dissection repair.](#)

[Shantel Chang](#)

2:36 pm

[Impact of a dedicated multi-disciplinary aortic team on survival after uncomplicated type B acute aortic syndrome](#)

[Sameer Bhat](#)

Purpose: Acute aortic syndromes (AAS) are associated with high mortality. While existing evidence suggests improved outcomes for type A AAS managed within specialised multidisciplinary aortic teams, it is unclear whether this association is also found for patients with type B AAS. This study assessed the impact of a multidisciplinary management approach on outcomes among patients with type B AAS. Methodology: This prospective cohort study included all consecutive adult patients aged ≥18 years old presenting with or referred to Waikato Hospital in Aotearoa New Zealand with type B or non-A/non-B AAS between January 2010 and December 2024. The primary outcome was mortality measured at 30-days and 1-year after presentation. Secondary outcomes included length of stay (LOS), unplanned 30-day readmission, and aortopathy panel testing. Variables were compared between patients presenting prior to (phase 1) and following the introduction of a multidisciplinary aortic team in mid-2020 (phase 2). Results: A total of 141 patients with type B AAS were included (phase 1, n=69; phase 2, n=72). The majority of presentations were aortic dissections (68.8%) and were uncomplicated in nature (73.0%). Baseline demographics and comorbidity profiles were similar between the two cohorts. Rates of 30-day (14.5% vs. 8.3%; p=0.38) and 1-year (26.1% vs. 12.5%; p=0.066) mortality trended towards an improvement after the introduction of a multidisciplinary aortic team. Hospital LOS (median 8 vs. 8.5 days; p=0.18) and 30-day readmission rates (17.4% vs. 6.9%; p=0.10) were not significantly different. Overall rates of genetic aortopathy testing increased significantly (10.1% vs. 44.4%; p<0.0001). Conclusion: This study suggests that a dedicated multidisciplinary aortic team may result in an improvement in medium-term survival among patients with type B AAS.

Further work is in-progress to determine whether this survival benefit persists in the long-term and how genetic results may guide type B AAS management.

2:44 pm

[The Stella Chart: Pilot Experimental Evaluation of Sheath-Sized Bovine Pericardial Conduits Using Intravascular Ultrasound](#)

[Tin Yau Ngan](#)

Background Back-table bovine pericardial conduits may be fashioned for small-calibre arterial reconstruction when autologous vein is unavailable. Their final pressurised diameter cannot be assumed from nominal introducer sheath size. We evaluated a pragmatic intravascular ultrasound-based sizing method and developed the Stella Chart. **Methodology** Bovine pericardial conduits were fashioned around 7, 8, 10 and 12 Fr Cook introducer sheaths using continuous 6-0 polypropylene with locking knots at 1-cm intervals. Each construct was submerged in saline, statically pressurised to 150 mmHg and assessed using intravascular ultrasound at three predefined locations. Measured luminal diameter was compared with sheath outer diameter, and longitudinal dimensional variation was calculated. **Results** Twelve intravascular ultrasound measurements were obtained across four constructs. Mean luminal diameters for the 7, 8, 10 and 12 Fr constructs were 2.9, 2.9, 4.1 and 5.3 mm, respectively. Within-construct variation was 0.1–0.3 mm. Relative to sheath outer diameter, achieved conduit diameter differed by –0.1 mm for 7 Fr, –0.4 mm for 8 Fr, +0.1 mm for 10 Fr and +0.7 mm for 12 Fr. The 7 and 8 Fr constructs converged at approximately 2.9 mm, while the 12 Fr construct expanded beyond its mandrel diameter. **Conclusion** Nominal sheath size did not demonstrate a linear relationship with final pressurised conduit diameter. Intravascular ultrasound enabled direct back-table verification and identified size-dependent behaviour not predicted by geometric calculation alone. The Stella Chart provides an empirical framework for constructing small-calibre bovine pericardial conduits when standard options are unavailable.

2:52 pm

[Discussion](#)
